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9A proportion of patients with early-stage cutaneous melanoma will eventually die 
of the metastatic disease. Prognostic factors are needed to identify this subgroup so 
that they can be allocated for more effective adjuvant treatments and surveillance. 
Biological prognostic factors may also serve as future treatment targets. The most 
common clinicopathological prognostic markers, i.e. tumour thickness (Breslow 
classifi cation) and level of tumour invasion (Clark classifi cation), were evaluated in 
a clinical retrospective series of 298 primary melanoma patients. In addition, tumour 
proliferation (Ki-67), Bcl-2, p53 and tumour vascularity (CD-31), were measured im-
munohistochemically in a subset of tumours and the results were related to disease 
outcome. In the search for new biological prognostic markers, expressions of the 
proteins tenascin-C (Tn-C) and ezrin were measured and related to the course of the 
disease. Further, in 18 patients the fi rst metastatic tissue specimen was analysed for 
Ki-67, Bcl-2 and p53 and in 12 patients for ezrin. The fi ndings were then compared 
with the corresponding immunohistochemistry of primary tumours.
The majority of the patients presented with localised stage I or II tumours at 
diagnosis; the overall survival rate at the 9.5-year follow-up was 66.8%. The most 
important factors determining the prognosis were tumour thickness, level of tumour 
invasion and stage at diagnosis. Other signifi cant adverse prognostic factors were 
tumour ulceration, tumour location on trunk and older age of patients. The width 
of the surgical resection margins had no effect on survival in any Breslow category. 
Strong immunoreactivity of Bcl-2 in primary melanomas was associated with adverse 
clinicopathological features such as male gender, older age and tumour ulceration 
and was associated with an adverse prognosis in intermediate thickness melanomas. 
Strong p53 immunoreactivity was an adverse prognostic factor for disease-free sur-
vival, whereas expression of Ki-67 had no prognostic value. In melanoma metastases, 
expressions of Bcl-2 and p53 were lower than in their primary counterparts, Ki-67 
showing no trends during disease progression. Patients with high tumour vascularisa-
tion showed a trend towards better overall survival. Expression of Tn-C had no corre-
lation with tumour staging. Positive immunoreactivity for Tn-C in invasive regions of 
the tumour and intracytoplasmically in melanoma islets was important in the progres-
sion of primary melanoma to metastatic disease but did not infl uence the prognosis 
signifi cantly thereafter. Expression of ezrin in primary melanoma was associated with 
tumour proliferation and tumour growth but was not a prognostic factor. Expression 
of ezrin was, in general, stronger in melanoma metastases than in primary tumours.
 In conclusion, the most important prognostic markers in this patient population 
with mainly localised primary melanomas were the stage of the tumour at diagnosis, 
and the thickness and invasion level of the tumour. Strong p53 expression was as-
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sociated with adverse disease-free survival, and strong Bcl-2 expression with other 
adverse clinicopathological features; Ki-67 expression was not a prognostic factor. 
High tumour vascularisation was associated with a better prognosis, but was not 
an independent prognostic factor. Absence of Tn-C in tumours was related to more 
benign disease behaviour and a lower risk of developing metastases. Expression of 
ezrin correlated with tumour proliferation (Ki-67), thickness and level of invasion, 
suggesting an association between ezrin expression and tumour progression, but did 
not reach prognostic signifi cance in survival analysis. 
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Melanoma has long been one of the fastest increasing malignancies in most Caucasian 
populations. In Finland, 716 new cases of primary melanoma and 155 deaths from 
melanoma were documented in 2003 (Finnish Cancer Registry 2005). Melanoma is 
most likely surgically cured if the tumour is thin (≤ 1.0 mm), superfi cial and non-
ulcerative, the 10-year survival rate being 88%. The thicker the tumour, the worse 
is the prognosis. The 10-year survival rate for patients with a melanoma 1.01 – 4.0 
mm thick is 51 – 79%, but for those with melanomas over 4.0 mm thick the rate is 
32 – 54%. If clinical lymph nodes are involved at diagnosis, the 10-year survival rate 
is 18 – 48% (Balch et al. 2001a). The major cause of death from melanoma is distant 
metastasis. Melanoma has traditionally been considered resistant to chemotherapy and 
radiation, and metastatic disease has a poor prognosis, with a median survival rate of 
6 months (Manola et al. 2000, Unger et al. 2001). The diffi cult problem facing us is 
to discover an oncological treatment that can cure systemic disease. As long as early 
surgery is the only reliable method to arrest disease progression, emphasis has to be 
on early accurate diagnostics, including the evaluation of prognostic parameters. 
 The clinical behaviour of individual melanoma patients is unpredictable and 
presents clinicians with a major challenge. Previous studies have reported that among 
superfi cial melanomas (Breslow score ‹ 1.0 mm) some tumours behave aggressively 
and metastasise early whereas some patients with thick melanomas do surprisingly 
well and survive for longer than expected (Spatz et al. 1998, Kalady et al. 2003). 
Melanoma has a multifactorial aetiology and much of its genetic and immunological 
background is still unknown. Research on melanoma biology including identifi ca-
tion of the factors crucial to melanoma development and progression, may help us 
to recognise the high-risk patients who might benefi t from more effective treatments 
and follow-up. Another hope is that we could develop successful targeted treatments. 
Much research has focused on fi nding prognostic markers for primary melanoma. So 
far tumour thickness (Breslow classifi cation) has remained the most important tu-
mour-related prognostic factor for localised primary melanoma. The second strongest 
predictor of disease outcome is tumour ulceration; the level of tumour invasion (Clark 
classifi cation) is a signifi cant factor only in thin melanomas (Balch et al. 2001a). 
Recent studies suggest that the presence or absence of dissemination of melanoma 
cells to the sentinel lymph node (SLN), the fi rst lymph node in the lymph basin drain-
ing from the tumour, is the most important factor in the prediction of disease outcome 
(Morton et al. 1992, Balch et al. 2004). 
 This thesis is based on a Finnish patient population (n = 298) treated for primary 
melanoma during 1988-1991 at Töölö Hospital, Helsinki University Hospital, with 
a median follow-up time of 9.5 years. The most important clinicopathological prog-
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nostic markers and the survival of patients are presented. In our search for biological 
prognostic factors we conducted immunohistochemical studies of tumour proliferation 
(Ki-67), the antiapoptotic protein Bcl-2, tumour-suppressor gene product p53, and tu-
mour vascularity (CD-31). All these results are compared with the results of previous 
reports. In addition, the expression patterns of two new biomarkers, tenascin-C and 
ezrin, are presented and correlated with classical tumour markers and the clinical out-
come of the patients. Understanding the clinical signifi cance of biological parameters 
of cutaneous melanoma may help us to select high-risk patients who could profi t from 
more effective treatments. 
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REVIEW OF THE LITERATURE
1. Primary melanoma 
1.1. Epidemiology
 
Cutaneous melanoma, a malignant lesion arising from the melanocytes, is less common 
than basal or squamous cell carcinoma of the skin but it is much more fatal (de Vries 
and Coebergh 2004). Between 1940 and the mid- to late-1980s, the incidence of inva-
sive cutaneous melanoma increased more rapidly than any other cancer in populations of 
predominantly Caucasian origin, the annual rate of increase being 3–7% (Diepgen and 
Mahler 2002). However, the incidence rates for melanoma show substantial variation 
worldwide (Lens and Dawes 2004). Currently, the highest rates have been reported from 
Australia, where the age-standardised rate for men is 39/100 000 and for women 30/100 
000. The lowest rates have been reported from China, 0.2/100 000 for both men and 
women (Ferlay et al. 2004). 
 In Northern Europe, where the incidence rates rose sharply during the 1980s, the 
rates seem to have been levelling off since the mid-1990s, especially in younger age 
groups. Primary prevention, i.e. less sun exposure, is thought to have been an impor-
tant factor contributing to these shifts (de Vries et al. 2003, Lindholm et al. 2004). In 
contrast, in Southern and Eastern Europe, the rates are continuing to rise steeply in 
all age categories (Severi et al. 2000). Over the last decades, increases in incidence 
have mainly been reported for thin melanomas, whereas the rate for thick melanomas 
seems to have been fairly stable (Lipsker et al. 1999, Murray et al. 2005). 
 Currently, the rising trend in mortality appears to have come to a halt, or even 
fallen, in the young and middle-aged in many populations with high melanoma inci-
dence rates, such as Australia and the United States and countries in North-Western 
Europe (La Vecchia et al. 1999, de Vries et al. 2003). One possible reason for this 
development is earlier diagnosis. However, there has been no sign of a downward 
trend in mortality in countries with lower incidence rates, e.g. in Southern Europe 
(Severi et al. 2000, de Vries and Coebergh 2004). In addition, high mortality rates 
have persisted among older men (Streetly and Markowe 1995, Buettner et al. 2005).
 In Finland, the incidence of melanoma rose continuously until the late 1980s, 
when it started to level off. In 2003, the incidence of melanoma was 9.3/100 000 (362 
new cases) among men, and 7.9/100 000 (354 new cases) among women (Finnish 
Cancer Registry 2005). According to the Finnish Cancer Registry, primary melanoma 
was the twelfth most common cancer among both men and women in Finland in 
2003. Since 1953, the mortality rates have consistently been higher in men than in 
women, reaching a peak of 2.6/100 000 in 1995, after which the rates declined slight-
14
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ly, being down to 2.3/100 000 in 2003. The mortality rates for women have remained 
fairly steady since the early 1970s, and in 2003 stood at 0.9/100 000 (Finnish Cancer 
Registry 2005). 
 
1.2. Risk factors for melanoma 
The precise cause of melanoma is unknown. The likelihood of cutaneous melanoma 
developing in a person depends on his or her constitutional predisposition, i.e. the geno-
typic and phenotypic characteristics, and subsequent exposure to environmental risk fac-
tors (Armstrong 2004). 
1.2.1. Environmental factors
Melanoma is primarily a disease of Caucasians. Among them, exposure to ultraviolet 
radiation (UVR) is the major environmental risk factor for melanoma, and is thought 
to be responsible for the increasing incidence of the disease (Thompson et al. 2005). 
Worldwide, the incidence of melanoma in Caucasians generally correlates inversely with 
latitude i.e. rates are generally higher close to the equator and become progressively 
lower in areas nearer to the poles (Ferlay et al. 2004). The association between UVR 
and melanoma is ambiguous, with differences in risk depending on the dose, the way the 
dose is delivered (intermittent or chronic) and the patient´s age (de Vries and Coebergh 
2004). Approximately 95% of solar UVR reaching the ground is UVA (wavelength 320 
to 400 nm), which penetrates deeper into the dermis while the remaining 5% is UVB 
(wavelength 290 to 319 nm), which is the radiation mainly responsible for erythematous 
response in the skin. UVB and probably also UVA are risk factors that can induce muta-
tions in skin cells and suppress immune reactions (Marks 1999). Intermittent, unaccus-
tomed exposure to UVR causing sunburns, especially during childhood and adolescence, 
has been postulated as the main risk factor for the development of melanomas (Desmond 
et al. 2003, de Vries and Coebergh 2004). Without repair of the damage, mutations in 
DNA can eventually result in the formation of melanoma, though the exact mechanisms 
of these mutations and events in the cells are still unknown (Owens and Watt 2003). 
 Commonly used sunscreens reduce the transmission of UVB to the skin, thus pro-
viding protection against the development of erythema but not the immunosuppres-
sion caused by UVA (Kelly et al. 2003, Poon et al. 2003). To date there is no evidence 
of the protective role of sunscreen use against the development of melanoma (Diffey 
2005). 
15
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1.2.2. Genes involved in melanoma susceptibility
Melanoma has a heterogeneous genetic aetiology. On the basis of population studies, it 
is suggested that approximately 5–12% of patients with melanoma have a family history 
of melanoma in one or more fi rst-degree relatives (Goldstein and Tucker 2001). Some of 
these patients have inherited a mutation in highly penetrant susceptibility genes that are 
associated with an increased risk of melanoma. Current genetic studies point to two such 
genes involved in cell cycle regulation: CDKN2A (Cyclin-Dependent Kinase Inhibitor), 
which is located on chromosome 9 (9p21) (Cannon-Albright et al. 1992), and CDK4 
(Cyclin-Dependent Kinase), which is located on chromosome 12 (12q13) (Zuo et al. 
1996). Inactivating mutations of CDKN2A confer a 50–90% risk of melanoma on carri-
ers by the age of 80 years (Bishop et al. 2002). Several families have been found to have 
mutations in CDK4 (Bishop et al. 2002). Penetrance of CDKN2A mutations is infl uenced 
by environmental or genetic factors, and it varies among populations with different 
melanoma incidence rates. The prevalence of CDKN2A mutation carriers is less than 1% 
in high-incidence melanoma populations. Moreover, uncertainties still exist regarding 
genotype/phenotype correlations of CDKN2A mutations. It is therefore recommended 
that predictive genetic testing for melanoma is carried out only in the context of clini-
cal research (Kefford et al. 2002). CDKN2A aberrations are found in 20% of sporadic 
melanomas (Bishop et al. 2002). A locus on chromosome 1p22 is strongly linked with 
melanoma susceptibility but the gene responsible has not yet been identifi ed (Gillanders 
et al. 2003).
 CDKN2A encodes two tumour suppressor proteins, p16 and p14ARF. p16 prevents 
entry of the cell into the cell cycle by inhibiting CDK4 phosphorylation of the retino-
blastoma protein (Serrano et al. 1993). p14ARF is induced in response to hyperprolife-
rative stimuli and is believed to induce p53-dependent cell cycle arrest or apoptosis 
(Sherr and Weber 2000). Mutations in CDK4, in turn, render the protein kinase CDK4 
resistant to p16 and are functionally equivalent to p16 loss (Soufi r et al. 1998).
 Variants in the gene of the Melanocortin-1 receptor (MC1R) have been cor-
related with an increase in melanoma in the general population and also in families 
with CDKN2A mutation. MC1R is activated upon hormonal stimulation and induces 
a production switch from pheomelanin to eumelanin. Loss-of-function mutations 
accompany a switch from eumelanin to pheomelanin production and are associated 
with red hair and fair skin (Valderve et al. 1995). MC1R gene is highly polymorphic, 
with more than 30 variants; individuals with several of these variants have a 2–4-fold 
increase in melanoma risk (Valderve et al. 1996). 
 Other important genes involved in melanoma are NRAS and BRAF genes. 
Mutations in BRAF are the most common in human melanoma, occurring in roughly 
80% of cultured tumours (Davies et al. 2002), whilst mutations in NRAS are identi-
fi ed in 15% of sporadic melanomas, and are associated with sun-exposed sites (van 
Elsas et al. 1996). Mutations in these genes cause activation of the Ras-Raf-MAPK 
pathway, a cascade involved in intracellular signalling, and result in an increase in 
16
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autocrine growth factors that can promote tumorigenesis. The activated Ras-Raf-
MAPK pathway can also lead to changes in gene transcription and resistance to apop-
tosis (Collisson et al. 2003).
Among the many other genes under active investigation is APAF-1, the apop-
totic protease activating factor that plays a central role in mitochondria-dependent 
apoptosis. Loss of Apaf-1 expression is encountered in 40% of sporadic melano-
mas (Soengas et al. 2001). PTEN (phosphatase and tensin homologue) is a tumour 
suppres sor gene (located at 10q23.3) that is involved in cell proliferation, survival, 
adhesion and migration. Loss of chromosome 10q has been detected in 30–50% of 
sporadic melanomas with an association of poor clinical outcome (Herbst et al. 1994). 
The tumour suppressor gene TP53 and its protein product, p53, are involved in cell 
cycle regulation. Normal p53 inhibits growth through activation of cell cycle arrest 
and apoptosis in response to DNA damage. Mutations in TP53 are rare in melanoma 
(Hussein et al. 2003). 
1.2.3. Chromosomal changes
Melanoma chromosomal pathogenesis is characterised not by specifi c structural abnor-
malities but rather by widespread aneuploidy (Casorzo et al. 2005). The chromosomes 
most frequently involved in structural rearrangements in melanoma are 1, 6, 7, 9, and 
11. Studies comparing the chromosomal status in primary and metastatic tumours of the 
same patient illustrate that losses of 9p and 10q are early events in tumorigenesis, where-
as loss of 11q and duplication of chromosome 7 appear to be later events (Albino et al. 
1993). Few prognostic studies exist. Nevertheless, patients with metastatic melanoma 
due to structural abnormalities of chromosomes 7 and 11 have had shorter survival times 
(Trent et al. 1990).
1.2.4. Host factors
Multiple (› 100) benign nevi are the most common clinical risk factors for melanoma 
(Berwick and Halpern 1997). Other minor risk factors for whites are blonde or red hair, 
the presence of freckles, and a fair skin type that is unable to tan. The risk of melanoma 
is increased in individuals with immunosuppression or with a history of blistering sun-
burn (Thompson et al. 2005). Individuals with large congenital melanocytic nevi are 
also at increased risk (relative risk of 101) for developing melanoma; cutaneous and/or 
extracutaneous. Individuals at greatest risk are those with very large, ≥50 cm congenital 
melanocytic nevi (Bittencourt et al. 2000). 
Dysplastic nevus syndrome is an important clinical risk factor for melanoma. An 
individual with this syndrome has 50 to 100 clinical atypical nevi on the upper trunk 
and limbs, some of them showing variability of size, outline and colour. Melanocytic 
dysplasia is seen in histologically atypical nevi. An individual with dysplastic ne-
vus syndrome has a relative risk of approximately 11 for developing melanoma 
(Armstong 2004). The genetic background of this syndrome is still unknown.
17
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 A melanoma patient has a relative risk of 8.5 for developing a second melanoma 
(Tucker et al. 1985). A strong family-history (≥ three fi rst-degree relatives affected) 
increases an individual´s relative risk of developing melanoma to 35–70 (Goldstein 
and Tucker 1995). Previous non-melanoma skin cancer also increases the relative risk 
of melanoma to 2.9 (Bower et al. 2000).
 Xeroderma pigmentosum is a rare, autosomal recessive genetic disorder char-
acterised by an inability to repair DNA damaged by UVR. Patients with xeroderma 
pigmentosum have a relative risk of more than 1000 for developing melanoma (Green 
et al. 2002), and almost 40% of reported melanomas among such patients occurred in 
children aged 12 years or younger (Lynch et al. 1967).
 
1.3. Diagnosis 
Primary cutaneous melanoma may develop in precursor melanocytic nevi (common 
acquired, congenital and atypical/dysplastic types) but more than 50% of cases are be-
lieved to arise de novo, without a pre-existing pigmented lesion (Tucker et al. 2002). The 
following clinical signs are suspicious for melanoma, especially the superfi cially spread-
ing type: asymmetry, border irregularity, colour variegation and a diameter exceeding 6 
mm. Even more important are changes to the lesion with respect to size, shape, shades of 
colour and surface features that may be signs of malignancy. Itching and tenderness of 
a lesion may indicate a malignant process (Abbasi et al. 2004). In clinical monitoring of 
patients with dysplastic nevus syndrome, total body photographs and dermoscopy can be 
used to detect new and changing nevi. 
 The clinical morphological spectrum of melanoma is broad and diverse, and 
includes non-pigmented tumours, which have a reported incidence of 1.6–10% 
(Thompson et al. 2005). If any suspicion of melanoma arises, the lesion should be 
submitted to histopathological analysis without delay. The standard procedure is limi-
ted but complete excision of the lesion including a narrow rim (2 mm) of normal skin. 
The diagnosis of melanoma depends on the results of the histological examination, 
no reliable marker having yet been found to replace the histological examination in 
melanoma diagnosis. Nevertheless, immunohistochemical analyses using antibodies 
to melanocyte differentiation antigens such as tyrosinase, gp100, Mart-1/Melan-A, 
MCAM and Mift are performed in histologically diffi cult cases such as amelanotic 
melanoma (Mangini et al. 2002). In differential diagnostics of the rare subgroup of 
desmoplastic neurotropic melanoma, the immunohistochemical analysis of p75 is 
used in conjunction with other markers (S-100, tyrosinase, HMB-45) (Kanik et al. 
1996).  
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1.4. Staging
In 2002, the American Joint Committee on Cancer (AJCC) introduced a new, evidence-
based melanoma staging system to replace the previous one, which dated from 1997 
(Tables 1 and 2) (Balch et al. 2004). The new staging system incorporates several major 
changes: (1) tumour (T) category thresholds of melanoma thickness are defi ned as 1.0, 
2.0 and 4.0 mm. Tumour thickness is now regarded as the primary determinant of tumour 
staging; (2) the Clark level of invasion is only used when defi ning subcategories of T1 
(thin ≤ 1.0 mm) melanomas, not for thicker melanomas (i.e. T2, T3 or T4); (3) ulceration 
has been added to the description of the primary tumour and is defi ned as the absence 
of intact epidermis overlying a major portion of the primary melanoma on the basis of 
microscopic examination of the epidermis (Balch et al. 2001a); (4) clinical satellites, 
microsatellites and in-transit metastases have similar prognostic implications, are catego-
rised as nodal (N) disease, and are placed in the regional stage III disease classifi cation; 
(5) the size of the lymph node as a prognostic factor has been eliminated and replaced 
by the number of positive nodes; this is regarded as the primary criterion. Pathological 
analysis of the tumour burden between micrometastases and macrometastases has been 
added to staging; and (6) the presence of an elevated serum level of lactate dehydroge-
nase (LDH) is used to defi ne the metastasis (M) category. 
 Clinical stages I and II are confi ned to patients with localised melanoma who 
have no evidence of metastases on the basis of clinical, radiological and/or labora-
tory examination. Stage III patients are those with a regional disease showing clinical 
or radiological evidence of regional micro- or macrometastases in either the regional 
lymph nodes, satellites or in-transit intralymphatic vessels. Stage IV melanoma pa-
tients have metastases at a distant site. 
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Table 1
Melanoma TNM classifi cation (AJCC 2002)
T classifi cation Tumour thickness (mm) Ulceration status
T1 ≤ 1.0 a=without ulceration and Clark 
level II/III
b=with ulceration or Clark level 
IV/V
T2 1.01 – 2.0 a,b
T3 2.01 – 4.0 a,b
T4 › 4.0 a,b
N classifi cation Number of metastatic nodes Nodal metastasis mass
N1 1 a=micrometastasis*
b=macrometastasis**
N2 2–3 a,b,
c=satellite(s)/in-transit 
metastasis(es) without metastatic 
nodes
N3 ≥ 4, or matted nodes, or in- 
transit met(s)/satellite(s) with 
metastatic node(s)
M classifi cation Site Serum LDH
M1a distant skin, subcutaneous or 
nodal metastasis 
normal
M1b lung metastasis normal
M1c all other visceral metastases,
any distant metastasis
elevated
*Micrometastases are diagnosed after sentinel or elective lymphadenectomy.
** Macrometastases are defi ned as clinically detectable nodal metastases 
confi rmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross 
extracapsular extension.
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Table 2
Stage groupings for cutaneous melanoma
           Clinical staging*          Pathological staging**
T N M T N M
0 Tis N0 M0 Tis N0 M0
IA T1a N0 M0 T1a N0 M0
IB T1b N0 M0 T1b N0 M0
T2a N0 M0 T2a N0 M0
IIA T2b N0 M0 T2b N0 M0
T3a N0 M0 T3a N0 M0
IIB T3b N0 M0 T3b N0 M0
T4a N0 M0 T4a N0 M0
IIC T4b N0 M0 T4b N0 M0
III any T
N1
N2
N3
M0
IIIA T1-4a N1a M0
T1-4a N2a M0
IIIB T1-4b N1a M0
T1-4b N2a M0
T1-4a N1b M0
T1-4a N2b M0
T1-4a/b N2c M0
IIIC T1-4b N1b M0
T1-4b N2b M0
any T N3 M0
IV any T any N any M any T any N any M
*Clinical staging includes microstaging of the primary melanoma and clinical/ 
radiological evaluation for metastases. By convention, it should be used after 
complete excision of the primary melanoma with clinical assessment for regional 
and distant metastases. 
**Pathological staging includes microstaging of the primary melanoma and 
pathological information about regional lymph nodes after partial or complete 
lymphadenectomy. Pathological stage 0 or stage 1A patients are the exception; they 
do not require pathological evaluation of their lymph nodes. 
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1.5. Prognosis
The single best indicator of the prognosis for patients with melanoma is the stage at 
their fi rst clinical presentation (Balch et al. 2001b). The patients at greatest risk include 
those with primary tumours › 4 mm thick and those with lymph node involvement. For 
in situ melanomas complete excision is curative. The overall prognosis for patients with 
localised melanoma is considered rather good. On the basis of the AJCC Melanoma 
Staging Database, which consists of 17 600 patients (Balch et al. 2001b), the 10-year 
overall survival rates for patients with stage I (primary tumour ≤ 1.0 mm) tumours was 
85% and for those with stage II (primary tumour › 1 mm) tumours 55%. In stage I and 
II localised melanomas, tumour thickness and ulceration were the two most powerful 
prognostic factors. In thin melanomas (≤ 1.0 mm), the level of invasion was more pre-
dictive of survival outcome than was tumour ulceration. In contrast, in melanomas › 1.0 
mm thick, tumour ulceration was more predictive than was level of tumour invasion. 
Other statistically signifi cant factors were the patient´s age and gender and the site of 
primary melanoma (extremity vs axial). In stage III melanomas, there were three sig-
nifi cant prognostic factors in multivariate analysis: the number of metastatic nodes, the 
tumour burden at the time of staging (e.g. microscopic vs macroscopic) and the presence 
or absence of ulceration of the primary melanoma. The prognosis among stage III group 
patients differed markedly, ranging from 69% of the 5-year survival rate for patients with 
nonulcerated melanomas (regardless of thickness) and a single occult nodal metastasis to 
13% of the survival rate for patients with ulcerated melanomas (regardless of thickness) 
with four or more clinically apparent nodal metastases (Balch et al. 2001b). The median 
duration of survival for the stage IV group of patients was 6–7.5 months from the time 
that distant metastasis was documented, whereas the 5-year survival rate was less than 
10%. In stage IV melanomas, the anatomical site of the distant metastases was the most 
signifi cant prognostic factor, the survival rate being higher for patients with nonvisceral 
metastases (i.e. skin, subcutaneous tissue and distant lymph nodes) than for those with 
visceral metastases (Balch et al. 2001b). 
 The histological status of the sentinel lymph node (SLN) has been considered an 
important predictor of disease-free and overall survival in many recent studies, Table 3. 
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Table 3 
Studies on sentinel lymph node biopsy and prognosis 
Study SLN negative patients
SLN positive 
patients
Statius Muller et al. 2001 (n = 263)
5-year DFS rate 
 
91% 49%
Doting et al. 2002 (n = 197)
3-year DFS rate
3-year OS rate 
83%
92%
66%
73%
Yee et al. 2005 (n = 836)
5-year OS rate 90% 56%
Leong et al. 2005 (n = 362)
5-year DFS rate
5-year OS rate
69%
69%
38%
60%
1.6. Clinical and histopathological prognostic factors 
The anatomical site of a primary tumour has proved to be an independent prognostic fac-
tor in many studies (Sondegaard and Schou 1985, Thorn et al. 1994, Balch et al. 2001b). 
Patients with lesions on the extremities, with the exception of the hands and feet, have 
a better prognosis than those with lesions on the trunk, head or neck. More specifi cally, 
the prognosis is particularly poor for patients with melanomas on the scalp, hands or 
feet (Balch et al. 2001b, Rogers and Braun 2002). However, contradictory results de-
monstrated that the primary location of the tumour in acral parts of the body was not an 
independent prognostic factor when tumour thickness and ulceration were considered 
using multivariate analysis (Wells et al. 1992). Neither was any prognostic signifi cance 
found when the tumour was located in the scalp, neck, upper back or outer arm (Evans 
et al. 1994). Data on the prognostic role of gender in melanoma are contradictory. Some 
investigators demonstrate that female gender is an independent prognostic factor regard-
less of tumour location, thickness or ulceration (Stidham et al. 1994, Balch et al. 2001b); 
others emphasise the difference in the presentation of melanoma in women, who tend 
to be associated with thin, nonulcerated tumours on extremities (Greenstein and Rogers 
1991, Vossaert et al. 1992, Thorn et al. 1994). The age of the patient is an independent 
DFS= disease-free survival
OS= overall survival
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prognostic factor for melanoma, higher age correlating with poorer survival regardless 
of tumour thickness or ulceration (Cohen et al. 1987, Austin et al. 1994, Balch et al. 
2001b). 
 In 1970, Breslow introduced the concept that prognosis correlated with tumour 
thickness, as measured in millimetres from the granular cell layer to the deepest 
part of the melanoma in a histological sample (Breslow 1970). Since then, numer-
ous studies have established tumour thickness as the most reliable tumour-related 
prognostic factor for localised primary melanomas (Balch et al 2001b, Nagore et al. 
2005). According to a recent study, the 10-year survival rate by tumour thickness is 
as follows: ≤ 1 mm 91%, 1.01–2.0 mm 78%, 2.01–4.0 mm 62%, and › 4.0 mm 38% 
(Carlson et al. 2003). Clark´s classifi cation, developed by Clark and coworkers in 
1969, determines the anatomical involvement of a tumour within the cutaneous and 
subcutaneous structures. The levels are as follows: level I – intraepidermal growth 
with intact basement membrane, level II – invasion of the papillary dermis, level III 
– tumour involvement fi lling the papillary dermis and involvement of the junction 
between the papillary and reticular dermis, level IV – invasion of the tumour into the 
reticular dermis, and level V – invasion of tumour cells into subcutaneous fat (Clark 
et al. 1969). In the current staging system, Clark´s classifi cation is considered to have 
prognostic value only in T1 melanomas. Tumour ulceration is an adverse prognostic 
indicator in stage I, II and III melanomas, but factors contributing to its formation are 
still unclear (Balch et al. 2001b). Among histopathological subtypes, the most com-
mon are superfi cially spreading melanoma and nodular melanoma, which constitute 
85% of tumours, the remaining 15% consisting of lentigo maligna, acral lentigious 
and desmoplastic melanomas. In general, there are no signifi cant prognostic dif-
ferences between the subgroups; rather they refl ect inherent thickness differences 
(MacKie 2000). For instance, nodular melanoma is, by defi nition, thicker than super-
fi cially spreading melanoma, and the prognosis of lentigo maligna melanoma is no 
better than that of other tumour types when stratifi ed by tumour thickness (Koh et al. 
1984, Kopf et al.1987). 
 Many studies have identifi ed vascular involvement of melanoma cells into 
the lumen of the vessel as an adverse prognostic factor (Straume and Akslen 1996, 
Kashani-Sabet et al. 2001). Microsatellites are discrete nests of tumour cells separated 
from the main body of the tumour. They occur infrequently in thin melanomas but 
their incidence increases in thick melanomas. The presence of microsatellites clearly 
predicts locoregional relapse and a few studies fi nd a signifi cant correlation between 
the appearance of microsatellites and a decreased disease-free survival rate (Day et al. 
1981, Harrist et al. 1984, Shaikh et al. 2005). The mitotic rate of an invasive tumour 
is defi ned as the number of mitotic fi gures observed per square millimetre. The major-
ity of large studies confi rm the mitotic rate as an important marker of disease outcome 
in melanoma (Retsas et al. 2002, Azzola et al. 2003). Regression in primary melano-
ma is a histological refl ection of host immune interaction with malignant cells, and is 
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encountered most often in thin tumours. Some authors have suggested that regression 
is a feature of thin metastasising lesions (Ronan et al. 1987, Mansson-Brahme et al. 
1994, Cook et al. 2002), but others have not attributed any signifi cant role to regres-
sion in explaining metastasis in thin melanomas (McGovern et al. 1983, Cooper et 
al. 1985). The presence of lymphocytes infi ltrating the base of the tumour during the 
vertical growth phase is a sign of an immune reaction to the melanoma cells by a 
host. The prognostic importance of the lymphocytes is an unsettled issue, some stud-
ies correlating their presence with a better prognosis (Sondergaard and Schou 1993, 
Clemente et al. 1996), others denying this (Thorn et al. 1994, Kopf et al. 1987). 
1.7. Prognostic serum markers for melanoma
The serum markers currently available for melanoma have only limited clinical use. 
Among those most widely used are lactate dehydrogenase (LDH), S-100β and melanoma 
inhibitory activity (MIA). As close correlations exist between their serum concentrations 
and tumour load, serum markers are not suitable for screening or for the diagnosis of pri-
mary melanomas (Ugurel 2005). Patients with distant metastases from melanoma who 
present with elevated serum levels of LDH, S-100β and MIA have poorer overall sur-
vival than do patients whose serum concentrations are within normal ranges (Vuoristo et 
al. 2000, Balch et al. 2001a and b, Ugurel 2005). 
 Several studies have focused on the use of reverse transcriptase polymerase chain 
reaction (RT-PCR) technology to detect melanin synthesis enzymes, most com-
monly tyrosinase and Mart-1, in melanoma cells circulating in the peripheral blood 
(Sarantou et al. 1997, Li et al. 2002). In a study comprising stages II and III clini-
cally free melanoma patients, determination of RT-PCR for tyrosinase and Mart-1 in 
the peripheral blood did not have a signifi cant impact on their prognosis; however, 
elevated serum levels of S-100β and MIA detected during follow-up examinations 
were signifi cantly associated with decreased recurrence-free survival rates (Garbe et 
al. 2003). 
1.8. Treatment of primary melanoma
1.8.1. Surgery
Surgery is the principal treatment method for primary melanoma. Current recommenda-
tions for excision margins of the primary tumour are based on prospective randomised 
studies of the World Heath Organization Melanoma Group (Veronesi et al. 1988), the 
Intergroup Melanoma Surgical Program (Balch et al. 1993), the Swedish Melanoma 
Study Group (Cohn-Cedermark et al. 2000), the French Group for Research on Malignant 
Melanoma (Khayat et al. 2003) and the British collaborative trial (Thomas et al. 2004). 
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For melanoma in situ, an excision margin of 0.5-1 cm is suffi cient. In invasive melano-
mas ≤ 1 mm thick, a margin of 1 cm is adequate. In melanomas 1.01–2.0 mm thick, 
the margins should be 1-2 cm; in melanomas 2.01–4.0 mm thick, the margins should 
be 2 cm; and in melanomas › 4 mm thick, margins of at least 2 cm are suffi cient. No 
randomised studies have directly compared 1-cm and 2-cm margins for melanomas 1–2 
mm thick. Consensus recommends, however, a 2-cm margin whenever it is anatomically 
feasible and a 1-cm margin in anatomically restricted areas. To date, only the British 
collaborative trial has evaluated excision margins for melanomas › 4 mm thick. The con-
clusion of this trial was that the excision margin for melanomas of this thickness should 
be 3 cm. Until more results are available from ongoing trials, the recommendation is for 
margins of at least 2 cm for › 4 mm melanomas (Thompson et al. 2005).
 The most recent methods for treating primary melanoma are biopsy and his-
topathological analysis of the sentinel lymph node (SLN). The concept of SLN is that 
the fi rst set of lymph nodes receives drainage and cancer cells from the primary tu-
mour site (Morton et al. 1992). According to the AJCC Melanoma Committee recom-
mendation, all melanoma patients with clinically node-negative regional lymph nodes 
who are considered for entry into surgical and adjuvant therapy clinical trials should 
have pathological staging with sentinel lymphadenectomy to ensure prognostic homo-
geneity (Balch et al. 2001a). In clinical practice, sentinel lymph node biopsy (SLNB) 
is recommended for all melanoma patients with tumours ≥ 1 mm thick or with inva-
sion level IV or V according to Clark´s classifi cation or with ulceration regardless of 
Breslow´s classifi cation (Testori and Mozzillo 2002). Patients with micrometastases 
in SLN have undergone reoperation involving dissection of the complete regional 
node fi eld. In positive SLN cases, however, there has been no evidence of metastatic 
disease in non-sentinel nodes in 87% of patients. A new multicentre trial has been 
launched to examine the necessity of complete node dissection for positive SLN 
cases (Morton et al. 2005). Knowledge of SLN status allows more accurate staging 
and provides a more reliable estimate of prognosis. These benefi ts are important not 
only for patients themselves, but also for stratifi cation in adjuvant therapy trials. The 
therapeutical results of sentinel lymph node biopsy concerning overall survival are 
still awaited with longer follow-up of multicentre trial (Morton et al. 2005). 
 Clinically evident metastatic disease in regional lymph nodes should be treated 
surgically, by complete regional node dissection, since 13–59% of such patients will 
not develop further metastatic disease (Balch et al. 2001b). Local recurrences and 
in-transit metastases are most effectively treated by surgical excision. Careful consid-
eration should be given to the choice of therapy for patients with numerous or large 
lesions, and for those with concurrent extraregional disease. Redissection of the nodal 
basin is recommended for recurrent regional lymph node metastases (Balch et al. 
2001b, Thompson et al. 2005). 
 Distant metastases are most common in subcutaneous tissue, liver, lung and brain 
(Balch et al. 2001b). The patients most likely to benefi t from resection of distant 
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metastases are those with a relatively small number of lesions (e.g. one to four) 
confi ned to the subcutaneous, nonregional lymph nodes, lung or brain, and a disease-
free interval of 1 – 2 years since resection of the primary lesion (Karakousis 1996). 
The excision of brain metastases has been shown to improve the survival of patients 
(Cattell et al. 2002). However, the resection of isolated pulmonary metastases or sub-
cutaneous recurrences is not generally considered curative though it may result in a 
signifi cantly prolonged disease-free interval (Wong et al. 1993, Karakousis 1996). No 
randomised clinical trials have been conducted on the effectiveness of the surgery of 
distant metastases. 
1.8.2. Radiotherapy
Melanoma has traditionally been considered as a malignancy resistant to radiotherapy. 
There are no randomised studies on the effi cacy of radiotherapy for melanoma although 
some clinical studies have shown benefi t acquired from radiotherapy (Ballo and Ang 
2003). For primary melanoma, radiotherapy is rarely indicated as an initial treatment 
option. It can be considered in special cases if surgery is not possible because of either 
the localisation or large size of the tumour or because of patient-related reasons (Ballo 
and Ang 2003). Postoperative radiotherapy can be delivered to lower the risk of local 
recurrence if the resection margins of the primary tumour are inadequate and if re-exci-
sion is not possible (Ballo and Ang 2004). Consensus has not been reached about the 
radiotherapy indications for localised disseminated melanoma, stage III (Ballo and Ang 
2004). According to some studies, radiotherapy can be considered as adjuvant treatment 
after complete lymph node dissection to reduce the risk of nodal basin recurrence in 
patients with clinically involved nodes, numerous metastatic lymph nodes, or any meta-
static node larger than 3 cm, metastatic involvement of the cervical or parotid region, or 
tumour growth outside the lymph nodes (Lee et al. 2000, Shen et al. 2000). For stage IV 
melanoma, radiotherapy can be used to palliate the neurological disorders, pain or com-
pression symptoms caused by distant metastases. Stereotactic radiotherapy provides an 
alternative therapeutic strategy for single brain metastases (Atallah and Flaherty 2005).  
1.8.3. Adjuvant therapy
To reduce the high risk (50%) of recurrences, postsurgical adjuvant therapy is considered 
for high-risk primary melanoma patients with thick (› 4 mm) tumours and/or locoregional 
metastatic lymph nodes (Balch et al. 2001a). An optional strategy in practice is treatment 
with interferon-α (INF-α). Several randomised trials have compared INF-α with control 
as adjuvant therapy for high-risk melanoma patients. The results of the individual trials 
on survival benefi t have, however, been somewhat inconclusive or even confl icting, pos-
sibly because of the difference in dosages (high/intermediate/low) and treatment dura-
tions of the INF-α used (Eggermont 2001, Middleton and Thatcher 2001, Kirkwood et 
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al. 2002, Kefford 2003). Randomised trials have shown that high-dose INF-α is the only 
treatment showing activity against melanoma, improving 5-year relapse-free survival 
(RFS) by approximately 10% compared with surgery alone. The impact of high-dose 
IFN-α on overall survival (OS) has been less clear (Kirkwood et al. 1996, Kirkwood et 
al. 2000). Meta-analysis comprising twelve trials consisting of comparisons of INF-α 
with control demonstrates some evidence for dose-response in terms of RFS but not of 
OS; hence, uncertainty remains as to the benefi ts of IFN-α in melanoma (Wheatley et al. 
2003). The use of INF-α as adjuvant therapy for primary melanoma patients has there-
fore to be evaluated in casu (Schuchter 2004). 
 Melanoma vaccines are designed to elicit a host immune response to tumour-asso-
ciated antigens. Autologous and allogeneic whole-cell preparations as well as purifi ed 
gangliosides, peptides, shed antigens and mechanical or viral melanoma cell lysates 
have been tested in laboratory or clinical studies (Livingston 2001). Thus far, ran-
domised trials have not shown any signifi cant benefi t for survival in adjuvant therapy 
for primary melanoma. The results of several ongoing trials are, however, awaited 
(Sosman et al. 2004). For the time being, the vaccine therapy is only indicated for 
melanoma patients participating in clinical trials.  
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2. Biology of melanoma 
The melanoma cell is the malignant counterpart of the normal melanocyte. Melanocytes 
located in the basal layer of the epidermis synthesise melanin pigment, which protects 
the body by absorbing solar ultraviolet light. The presence of melanocytes has also been 
confi rmed in mucosa in the head and neck, oesophagus, small bowel, anorectum and 
urogenital tract. Primary mucosal melanoma represents a rare malignancy that is often 
diagnosed at a later stage and has a poorer prognosis than cutaneous melanoma (Chang 
et al. 1998). There are three types of ocular melanoma: uveal, cutaneous and conjunc-
tival, all of which differ in epidemiology, pathogenesis and metastatic pattern (Devron 
and Char 2003). In an American cancer database report of 84 836 melanoma patients, 
91.2% had cutaneous, 5.2% ocular, 1.3% mucosal and 2.2% unknown primary tumours 
(Chang et al. 1998). 
 Melanoma develops as a result of accumulated abnormalities in genetic pathways 
within the melanocyte. These abnormalities promote cell proliferation and increase 
apoptosis resistance (Meyskens et al. 2004). Genetic changes are expected to take 
place at the transition from a benign nevus to a dysplastic nevus, in situ melanoma or 
radial growth phase melanoma. Additional genetic activation is thought to take place 
at the transition from the radial to the vertical growth phase of melanoma, which 
has an invasive and expanding growth pattern (Herlyn and Satyamoorthy 2001). 
Melanoma cells of the vertical growth phase have escaped from the control of ke-
ratinocytes and migrated into the dermis, where they proliferate independently of exo-
genous growth factors, tumour cell growth relying more on autocrine stimulation and 
the infl uence of the tissue microenvironment (Sections 2.4. to 2.7.) Vertical growth 
phase melanoma cells are tumorigenic and have metastatic competence (Herlyn and 
Shih 1994). This has been shown both in human patients and in experimental animal 
models (Kath et al. 1991, Juhasz et al. 1993). In the course of melanoma progression, 
tumour cells invade the surrounding host tissue stroma, separate from the primary 
tumour mass and migrate through the extracellular matrix to enter into the lymphatic 
or vascular system. In close contact with neighbouring cells, cell adhesion molecules 
direct and organise the interaction between cells (Johnson 1999). Angiogenesis, the 
formation of new vasculature, is needed for the tumour to attain a diameter exceeding 
1 – 2 mm (Folkman 1990). 
2.1. Cell cycle regulation 
Tumour growth is regulated by a balance between cell proliferation, growth arrest and 
cell death. The normal cell cycle is regulated by multiple proteins interacting in a fi ne, 
complex sequence. Mitogenic growth factors promote the entry of quiescent cells into 
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the fi rst gap phase (G1) and the initiation of DNA synthesis (S phase) of the cell cycle. 
The second gap phase (G2) is then followed by mitosis. 
 The retinoblastoma (Rb) tumour suppressor protein in the G1 phase constitutes a 
key pathway known to be dysregulated in many malignancies. In melanoma patho-
genesis, the p16-Cyclin D/Cdk4-pRb pathway functional unit is frequently altered, 
the function of Rb commonly being inhibited by hyperphosphorylation. Loss of p16 
function is associated with progression of disease (Straume et al. 2000).
 Ki-67, proliferating cell nuclear antigen, PCNA (a polymerase accessory protein, 
peaking in the G1/S phase), S phase fraction and silver-stained nucleolar organiser 
regions (AgNORs) are all reliable and widely used means for measuring the growth 
fraction, e.g. the proliferation index, and have been shown to be independent prog-
nostic factors in small melanoma cohorts (Stone et al. 1996, Karjalainen et al. 1998, 
Barzilai et al. 1998, Korabiowska et al. 2000). In addition, cell-cycle regulators such 
as cyclins A and D3 correlate with growth fraction markers and independently predict 
prognosis in subsets of patients with melanoma (Florenes et al. 2000, Florenes et al. 
2001). Accordingly, several studies have associated mitotic count with decreased sur-
vival of melanoma patients (Retsas et al. 2002, Azzola et al. 2003).  
 c-myc is a gene acting as one of the central regulators of cell proliferation. It can 
induce G1 entry in the absence of external growth factors. Moreover, c-myc can initi-
ate apoptotic cell death in the presence of wild-type p53 protein or under conditions 
of growth factor deprivation. In subgroups of patients, e.g. those with acral primary 
melanomas, c-myc gene amplifi cation has been an independent adverse prognostic 
factor (Ross and Wilson 1998, Grover et al.1999). 
2.1.1. Ki-67
Ki-67 is a high molecular weight nuclear protein that is expressed during the cell cycle 
in late G1, M, G2 and S phases but not during early G1 and G0 phases or resting cells; 
thus it is a marker of proliferation. Mib-1, a monoclonal antibody used to detect Ki-67 in 
paraffi n-embedded tissue, was fi rst described by Gerdes (Gerdes et al. 1984). 
 In primary melanoma of the skin, proliferative activity has been studied by several 
methods, e.g. mitotic counts, fl ow cytometry and immunohistochemical staining with 
Ki-67 antibody. Mutation of cell cycle regulators can lead to an increased percentage 
of cells entering the S phase, thus causing proliferation of a tumour. Some authors 
have described an increase in proliferative activity in primary melanoma with increas-
ing tumour thickness (Moretti et al. 1990, Rieger et al. 1993, Hazan et al. 2002). The 
use of proliferative markers, such as Ki-67, as indicators of clinical outcome has been 
demonstrated in several types of malignant tumour, e.g. breast cancer (van Dienst et 
al. 2004), lung cancer (Martin et al. 2004), and renal cell carcinoma (Kallio et al. 
2004). Some studies have reported associations between increased Ki-67 expression 
and poor survival in thick melanomas (Ramsay et al. 1995a, Böni et al. 1996, Vogt 
et al. 1997). However, studies on tumours with a wider range of thickness have not 
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found any correlation between Ki-67 expression and disease outcome (Reddy et al. 
1995, Talve et al. 1996a, Stone et al. 1996, Hazan et al. 2002). One study has demon-
strated differing correlations between Ki-67 expression and prognosis, depending on 
tumour thickness; positive Ki-67 immunoreactivity was associated with a higher risk 
of metastasis in melanomas equal to or less than 1.5 mm thick and with a lower risk 
of metastasis in melanomas thicker than 1.5 mm (Moretti et al. 2001). 
2.2. p53
The p53 gene was discovered in the late 1970s encoding a cellular 53kd nuclear phos-
phoprotein called the wild-type protein p53. p53 has characteristics of a tumour-suppres-
sor gene as a controller of the G2/M checkpoint of the cell cycle, a participator in DNA 
repair and an inductor of G1 arrest of cell proliferation (Hussein et al. 2003). It inhibits 
DNA synthesis following DNA damage. p53 also plays a role in programmed cell death 
by decreasing expression of Bcl-2 and increasing that of Bax (Harris and Hollstein 1993, 
Miyashita et al. 1994). Additional functional properties of p53 are its ability to activate 
many promoters and interact with numerous cellular and viral proteins. Loss of these 
functions, either through mutations or by allelic deletion, leads to enhanced genomic in-
stability, gene amplifi cation and changes in DNA ploidy (Livingstone et al. 1992). These 
alterations are associated with transformation in vitro and development of neoplasias in 
vivo (Levine et al. 1991) with resistance of p53-dependent apoptosis. 
 p53 is a frequently mutated gene, with more than 50% of human malignancies 
harbouring defects in it (Levine et al. 1991, Lee et al. 1994). UVR has been docu-
mented to cause p53 mutations in squamous cell carcinoma and melanoma of the 
skin (Weiss et al. 1993, Ziegler et al. 1994). p53 mutations have been detected in up 
to 60% of squamous cell carcinomas, in contrast to melanomas where mutations are 
rare, less than 5% (Ziegler et al. 1994, Hussein et al. 2003). 
 The mutant p53 protein has a half-life of several hours, in contrast to the wild-type 
protein´s half life of about 25 minutes (Reich and Levine 1984). Therefore the mutant 
form accumulates in the cell and is more easily detectable in immunohistochemistry. 
The p53 function can also be lost without mutations, as wild-type p53 can form inac-
tive complexes with other proteins. High levels of wild-type p53 can be detected in 
benign cells of the skin with DNA damage caused by, for instance, UVR (Hall et al. 
1996). Thus, a high level of p53 expression detected in immunohistochemistry is not 
necessarily caused by a mutated p53 gene. This fi nding may partly account for the 
heterogeneous results of p53 expression in melanoma. In addition, the diversity of 
results obtained in studies on p53 alterations in melanoma may be attributed to dif-
ferently assessed immunohistochemistry, the genetic heterogeneity of melanomas and 
the presence of several mechanisms for p53 gene mutations (Hussein et al. 2003). 
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 The clinical signifi cance of p53 mutations has been the subject of a number of 
controversies. Loss of p53 function has been correlated with shortened survival of 
patients with various carcinomas, e.g. of the breast, lung, colorectum and gastrum, 
in which it has been an unfavourable prognostic factor (Hollstein et al. 1997). Some 
studies on primary melanoma have shown no correlation between p53 expression and 
melanoma prognosis (Reddy et al. 1995, Weiss et al. 1995, Stone et al.1996, Talve et 
al. 1996b). Others, in contrast, indicate an association between high p53 expression 
and poorer disease outcome (Vogt et al. 1997). 
2.3. Apoptosis
Apoptosis, i.e. programmed cell death, is induced by excessive exposure to UVR or 
DNA damage. p53 is a central sensor responding to various stimuli to induce the apop-
totic pathway although other apoptotic pathways also exist. In melanoma, p53 mutations 
can alter the apoptotic pathway, although the frequency of mutations is rare. Loss of 
p53 function leads to the survival of damaged cells, thereby allowing tumour develop-
ment (Ziegler et al. 1994). In the p53 apoptotic pathway, cytochrome c is released from 
mitochondria, inhibited by anti-apoptotic proteins such as Bcl-2/Bcl-xL. In the apoptotic 
sequence, Apaf-1 is activated and complexes are formed with caspase-9 and the effector 
caspase family, leading to cell death. Apaf-1-mediated apoptosis is inhibited by Akt/PKB 
and by IAP (inhibitors of apoptosis proteins). It has been reported that melanoma cells 
can avoid apoptosis by inactivating Apaf-1 (Soengas et al. 2001). Survivin and livin, two 
members of the IAP family, can also regulate apoptosis. Strong survivin expression has 
been described in invasive and metastatic melanoma (Grossman et al. 1999). 
2.3.1. Bcl-2
Bcl-2 is the acronym for the B-cell lymphoma/leukaemia-2 gene. Bcl-2 belongs to a mul-
tigene family that consists of genes encoding proteins with different functions, as inhibi-
tors of apoptosis (Bcl-2, Mcl-1 and Bcl-XL) and as promoters of cell death (Bax and Bcl-
XS). Interactions among proteins in this family regulate the sensitivity of cells to apop-
totic stimuli (Reed 1994). The bcl-2 gene was fi rst discovered through its involvement 
in B-cell malignancies, in which (14:18) chromosomal translocations activate the gene 
in the majority of follicular non-Hodgkin´s B-cell lymphomas (Tsujimoto et al. 1985). 
The consequence of this translocation is deregulation of bcl-2 and overexpression of the 
protein product that resides predominantly in inner mitochondrial protein, though it is 
also found in the nuclear and cellular membranes (Ramsay et al. 1995b). The detailed 
mechanism of action at the biochemical level is still not known (Coultas and Strasser 
2003). It has been proposed that altered bcl-2 results in dysregulated programmed cell 
death, allowing cells that were programmed to die to persist and accumulate (Reed 
1994). Accumulation of cells with aberrant bcl-2 has had tumorigenic potential in 
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lymphoproliferative disorders in mice (McDonnell et al. 1989). The same translocation 
has been discovered in normal tissue and in other neoplasias. The prognostic role of 
Bcl-2 in clinical studies on different malignancies has varied: expression of Bcl-2 has 
correlated with prolonged patient survival, e.g. in non-small cell lung cancer (Kren et 
al. 2004) and in renal cell carcinoma (Kallio et al. 2004). However, in other forms of 
cancer, e.g. prostatic cancer (Quinn et al. 2005) and classical Hodgkin´s lymphoma (Sup 
et al. 2005), expression of Bcl-2 has been an adverse predictor of the disease. 
 Human primary melanoma expresses Bcl-2 in up to 90% of cases (Cerroni et al. 
1995, Tron et al.1995, Grover and Wilson 1996). In normal skin, Bcl-2 is detected as 
cytoplasmic staining along the basal layer of the epidermis, with variation depending 
on the localisation of the samples (van den Oord et al. 1994). Bcl-2 is also expressed 
in normal melanocytes (Ramsay et al. 1995b). The importance of Bcl-2 in the deve-
lopment and progression of melanoma is still disputed. Some studies report that its 
expression in primary melanoma is lower than in benign nevi (Ramsay et al. 1995b, 
Tang et al. 1998), whereas another study demonstrates an increase in Bcl-2 during 
disease progression (Leiter et al. 2000). Yet other investigators showed that Bcl-2 
levels did not change during tumour progression and did not differ from expression in 
normal melanocytes (Cerroni et al. 1995, Plettenberg et al. 1995, Selzer et al. 1998). 
In addition, some studies have demonstrated an inverse correlation between increas-
ing tumour progression to metastasis and Bcl-2 expression (van den Oord et al. 1994, 
Ramsay et al. 1995b, Tron et al. 1995). An association was reported between poor 
outcome and maintenance of Bcl-2 expression in regional metastatic lesions (Grover 
and Wilson 1996). In one study analysing changes in Bcl-2 expression during the 
course of the disease from primary melanoma to metastatic phase, Bcl-2 expression 
was higher in primary melanomas that later metastasised than in controls in which the 
disease remained localised, a fi nding suggesting a possible predictive role for Bcl-2 
expression (Hernberg et al. 1998). 
2.4. Growth factors 
Melanoma cells express different growth factors and cytokines and their receptors during 
tumour progression, which, through autocrine and paracrine effects, enable the cells to 
grow autonomously and confer competence to metastasis (Lazar-Molnar et al. 2000). 
Autocrine growth factors, e.g. basic fi broblast growth factor (bFGF), interleukin-8 (IL-
8), IL-10, melanoma growth stimulatory activity/growth-regulated protein (MGSA/GRO) 
and platelet-derived growth factor A (PDGF-A), produced by melanoma cells stimulate 
proliferation of the producing cell itself, whereas paracrine growth factors, e.g. platelet-
derived growth factor (PDGF), endothelial growth factor (EGF), transforming growth 
factor-β (TGF-β), IL-1, insulin-like growth factor-1 (IGF-1) and vascular endothelial 
growth factor (VEGF), contribute to the tumour growth indirectly, affecting the microen-
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vironment of the tumour or suppressing the immune system, thus making it benefi cial for 
tumour growth, invasion and metastasis (Halaban 1996). Host tissue cells for their part 
produce various activating growth factors, e.g. insulin growth factor-I (IGF-I), PDGF 
and scatter factor, as well as inhibitory growth factors, e.g. IL-1, IL-6, TGF-β, tumour 
necrosis factor (TNF) and interferons for melanoma cells. Inhibitory effects occur main-
ly in early-stage melanomas, diminishing and disappearing as the tumour progresses. In 
some cases, an inhibitory growth factor can switch to an autocrine stimulator when the 
tumour itself begins to produce it in an autocrine manner, thus enhancing its own prolif-
eration (IL-6, TGF-β) (Lazar-Molnar et al. 2000).
 Clinical studies have correlated IL-8 expression with the patient´s clinical course, 
with time to progression being signifi cantly reduced in primary tumours expressing 
IL-8 in either the tumour cells or keratinocytes of the overlying epidermis (Nurnberg 
et al. 1999). In another study, IL-8 over-expression was discovered in primary 
melanomas compared with metastatic samples of the same patients, however, no cor-
relation was found between IL-8 expression and survival (Gutman et al. 2002). 
 The secretion of the lymph vessel-specifi c VEGF-C and -D of melanomas has 
been associated with the formation of new lymph vessels and an increased risk of 
lymph node metastases (Nathanson 2003). 
2.5. Angiogenesis
Angiogenesis refers to the formation of new blood vessels. Induction of angiogenesis 
is required for most tumours to grow beyond 1 to 2 mm in diameter, the limit of the 
simple diffusion of nutrients and oxygen (Folkman 1990). Angiogenesis is controlled 
by angiogenic factors that can be secreted by tumour cells, infl ammatory cells and stro-
mal cells (Fox 1997). Several angiogenic growth factors have been identifi ed, including 
VEGF, bFGF, PDGF, TGF-α and -β and angiogenin, as well as angiogenic inhibitors e.g. 
angiostatin, thrombospondin-1, endothelial monocyte activating polypeptide II and en-
dostatin (Srivastava et al. 2003). In contrast to nonneoplastic angiogenesis, which has a 
certain end-point, a tumour induces angiogenesis almost continuously until the neoplasm 
is eliminated or the host dies (Folkman and Klagsbrun 1987). Moreover, tumour-associ-
ated endothelial cells are stimulated to degrade the basement membrane and to migrate 
into the perivascular stroma. Migrating endothelial cells produce type IV collagenase 
and other members of the matrix metalloproteinase family (Ausprunk and Folkman 
1977). Proliferating endothelial cells also release growth factors that may stimulate the 
tumour (Folkman 1992). 
 Angiogenesis permits solid tumour growth. For clinical metastases to occur, tu-
mour cells must fi rst enter the circulation, evade the host immune response, adhere to 
the capillary wall in a suitable tissue, leave the circulation and then establish a new 
tumour vasculature that will permit growth. Tumour vascularity has been proposed as 
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a prognostic marker for a number of solid tumours such as lung cancer (Singhal et al. 
2005), prostatic cancer (Quinn et al. 2005), head and neck squamous cell carcinoma 
(Smith et al. 2001) and breast cancer (Choi et al. 2005). These studies indicate that 
an increased number of microvessels within the primary tumours correlates with a 
higher metastasis rate or recurrence. The capacity of cutaneous melanoma to induce 
angiogenesis is well established (Fallowfi eld and Cook 1991, Barnhill et al. 1992), 
but the importance of angiogenesis in melanoma progression is controversial. 
 It has been demonstrated that in situ tumours are avascular and that the onset of 
angiogenesis ushers in a phase of rapid growth (Folkman and Klagsbrun 1975). In 
contrast, other studies have shown that there has been increased vascularity in the 
dermis beneath melanoma in situ, suggesting that tumour angiogenesis precedes inva-
sion and that invasion and metastatic spread are due to some other intrinsic change 
in the melanoma cells themselves (Fallowfi eld and Cook 1991). The prognostic role 
of tumour vascularisation in melanoma is undetermined, some studies reporting that 
increased vascularity in melanoma is associated with a poorer prognosis (Srivastava 
et al. 1988, Rongioletti et al. 1996, Neitzel et al. 1999, Kashani-Sabet et al. 2001, 
Zamolo et al. 2001), others fi nding no such association (Carnochan et al. 1991, 
Barnhill et al. 1994, Busam et al. 1995, Lin et al. 1999). 
2.6. Adhesion molecules 
Adhesion molecules can be grouped into integrins, the immunoglobulin superfamily 
and cadherins. Integrins link the cell membrane to the cytoskeleton, mediate adhesion 
to extracellular matrix (ECM) components and to other cells, and transfer signals to the 
cell inducing changes in gene expression (van der Flier and Sonnenberg 2001). Integrins 
α4β1 and αvβ3 have been correlated with invasive and metastatic potential in melanoma 
cell lines. Expression of αvβ3 integrin has predicted a short recurrence-free interval in 
clinical stage I and short overall survival in intermediate thickness melanoma (Natali et 
al. 1997, Hieken et al. 1999). 
 As well as mediating adhesion, members of the immunoglobulin superfamily 
serve as receptors for integrins and ECM proteins. One of these, melanoma cell adhe-
sion molecule (MCAM; previously known as Mel-CAM or MUC18), is a cell surface 
glycoprotein that is rarely observed in nevus cells but is increased in melanoma cell 
lines, correlating directly with enhanced growth and metastatic capacity of the cells 
(Luca et al. 1993, Xie et al. 1997). MCAM is also upregulated as melanomas enter 
the vertical growth phase (Newton-Bishop 1997), but to date there are no reports of 
the prognostic impact of MCAM in melanoma. Expression of intercellular adhesion 
molecule-1, ICAM-1, is strongly upregulated in melanoma cells as compared with 
benign melanocytic lesions. Increased expression is associated with poor prognosis 
in stage I melanomas (Natali et al. 1997). Activated leukocyte cell adhesion molecule 
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(ALCAM) is thought to mediate clustering of melanoma cells, and its expression 
has been correlated with increasing vertical thickness (van Kempen et al. 2000). No 
prognostic studies exist on ALCAM in melanoma. Cell surface glycoprotein CD44 
and its ligand, extracellular matrix component hyaluronan (HA), maintain adhesive 
restraints between the cells in normal epidermis (Soukka et al. 1997). Although some 
studies suggest that CD44 and HA enhance the growth and metastatic capacity of 
melanoma cells (Guo et al. 1994, van Muijen et al. 1995), the clinical importance of 
CD44 expression for prognosis remains controversial (Harwood et al. 1996, Dietrich 
et al. 1997).  
 Cadherins, both E- and N-subtypes, are important molecules in the morphogenesis 
and maintenance of skin structure, and they determine the location of melanocytes in 
the skin (Tang et al. 1994). In normal skin, E-cadherin is expressed on the cell surface 
of keratinocytes and melanocytes whereas N-cadherin is expressed by fi broblasts and 
endothelial cells. In vitro and in vivo studies report that during melanoma progres-
sion, there is a switch from the predominance of E-cadherin to that of N-cadherin, 
freeing melanocytes from the control of keratinocytes and enabling them to interact 
directly with other N-cadherin-expressing cells such as vascular endothelial cells 
(Hsu et al. 1996, Seline et al. 1996). One clinical report on melanomas with high 
expression of E-cadherin together with S100A4 negativity noted a signifi cant associa-
tion with favourable disease-free survival (Andersen et al. 2004). 
2.7. Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are proteolytic enzymes that remodel and degrade 
the tumour surrounding extracellular matrix and basement membrane in the process of 
tumour invasion. MMPs are secreted from melanoma cells and from surrounding cells 
of the stroma. Increased expression of MMP-1, -2, -9 and -13 has been correlated with 
an invasive melanoma phenotype in human melanoma cell lines (Hofmann et al. 2000). 
High MMP-2 immunoreactivity in melanoma cells of the primary tumour has been re-
ported to be an independent unfavourable prognostic factor and correlated with later 
haematogenous metastasis (Väisänen et al. 1996, Väisänen et al. 1998). In a clinical se-
ries of primary melanoma there was no clear association with the immunohistochemical 
expression of MMP-2 and tumour progression, and serum levels of MMP-2 and MMP-9 
were not specifi c in showing melanoma progression (Redondo et al. 2005). Previous re-
ports have suggested that high expression levels of MMP-1 and MMP-3 have correlated 
with shorter disease-free survival in human metastatic melanoma (Nikkola et al. 2002) 
and that patients with high serum MMP-9 levels have had signifi cantly poorer OS than 
patients with lower serum MMP-9 levels (Nikkola et al. 2005). 
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2.8. Tenascin-C
Tenascin-C (Tn-C) is a member of the extracellular matrix (ECM) protein family. 
ECM is composed of various molecules such as hyalyronic acid, proteoglycanes, gly-
cosaminoglycanes, elastin and collagen, and of glycoproteins such as fi bronectin, vit-
ronectin, laminin and tenascin. ECM forms a supporting network to which cells adhere; 
further it acts as an information system in coordinating signals originating from the tis-
sue microenvironment and adjacent cells (Chiquet-Ehrismann and Chiquet 2003). 
 The human tenascin group includes tenascin-C, -R, -X and -W. Discovered inde-
pendently by several research groups, Tn-C is the founding member of the family, 
as a protein enriched in the stroma of the gliomas (Bourdon et al. 1983) and as a 
myotendinous antigen (Chiquet and Fambrough 1984). Tn-C is a large glycoprotein 
consisting of six identical subunits built from variable numbers of repeated domains, 
each domain including heptad repeats, endothelial growth factor (EGF)-like repeats, 
fi bronectin type III domains and a C-terminal globular domain (Jones and Jones 
2000). In cell cultures, several Tn-C isoforms have been identifi ed (Latijnhouwers et 
al. 2000). Tn-C is expressed transiently during embryogenesis and foetal development 
and in a restricted pattern at sites of cell proliferation, migration and ECM remodel-
ling in adult tissues. Correspondingly, in clinical settings, Tn-C is expressed in acute 
infl ammation, wound healing, regeneration and neoplastic processes in adult tissues 
(Jones and Jones 2000). 
 Tn-C is synthesised mainly by dermal fi broblasts but, in some conditions, by 
epidermal keratinocytes, too (Latijnhouwers et al. 2000). In-situ hybridisation stud-
ies have shown that tumour cells can also act as a source of Tn-C, as in melanomas 
and in basal cell and squamous cell carcinomas (Herlyn et al. 1991, Tuominen et al. 
1997). Tn-C is not detected in normal mesencymal tissues, e.g. muscle or adipose or 
fi brous connective tissue, but neo-expression of Tn-C has been shown in more than 
50% of the rhabdomyosarcomas, fi bromas and liposarcomas (Schnyder et al. 1997). 
Expression of tenascins is regulated by cytokines, vasoactive peptides, other ECM 
proteins, biomechanical factors, and a variety of growth factors, i.e. members of the 
TGF-β family (Jones and Jones 2000, Chiquet-Ehrismann and Chiquet 2003). 
 The function of Tn-C is complex, and Tn-C isoforms have been found to have 
different effects on the adhesion, migration and proliferation of cultured cells 
(Latijnhouwers et al. 2000). In experimental set-ups, Tn-C can act adhesively for one 
cell type and inhibit the adhesion of another. The effect of Tn-C on a single cell may 
also vary, depending on the cell´s contacts with the other ECM components. Previous 
studies show that tenascins generally interfere with the integrin-dependent spreading 
of most cell types (Chiquet-Ehrismann and Chiquet 2003). 
 The suggested role of Tn-C in malignant neoplasias is complex. As Tn-C contains 
epidermal growth factor-like repeats, it may induce tumour growth through an au-
tocrine mechanism (Engel 1989, Jones and Jones 2000). Experimental studies show 
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that it also seems to be involved in angiogenesis. Tn-C stimulates endothelial-cell 
migration and mitogenesis and growth-factor-dependent endothelial cell sprouting. 
In addition, Tn-C is a major constituent of the ECM surrounding angiogenic blood 
vessels (Jones 2001). ECM proteins take part in stromal-epithelial interactions dur-
ing tumour invasion. The basement membrane is lost during cell invasion and Tn-C 
may be involved in the detachment of cancer cells, promoting their invasive potential 
(Shintani et al. 1997). 
 In the normal human skin Tn-C is expressed in the upper dermis, where it may 
be virtually absent or reveal patchy expression along the basement membrane. 
Immunohistochemical staining is intense around hair buds, eccrine glands and the 
intima of larger blood vessels. Similar strong expression of Tn-C has been detected 
along the basal membrane, extending to the deeper dermis in psoriasis and basal cell 
carcinoma, thus indicating its unspecifi c appearance in different tissues (Schalkwijk 
et al. 1991). Although Tn-C is not indicative of malignancy, its expression in melano-
cytic tumours is higher during tumour progression. 
 Moderate expression has been detected in benign and dysplastic nevi at the der-
moepidermal junction and in the papillary dermis. In invasive melanomas, Tn-C expres-
sion has been stronger and has extended deeper into the reticular dermis. In melanoma 
metastases, Tn-C expression has been greatly increased. In addition, intracytoplasmic 
Tn-C has been detected both in primary and in metastatic melanomas (Tuominen and 
Kallioinen 1994). To our knowledge, there are as yet no studies correlating the fi ndings 
of Tn-C expression in melanoma and the clinical course of the disease.
 Previous studies show that Tn-C expression increases during disease progression 
from benign to preinvasive and to invasive forms, e.g. in colorectal tumours (Riedl 
et al. 1992), endometrial tumours (Sasano et al. 1993), transitional cell tumours of 
the urinary bladder (Tiitta et al. 1993), gastric tumours (Ilunga and Iriyama 1995), 
adenoid cystic tumours of the salivary glands (Shintani et al. 1997), lung tumours 
(Kusagawa et al. 1998), prostate tumours (Xue et al. 1998), laryngeal tumours 
(Yoshida et al. 1999) and breast tumours (Goepel et al. 2000).  
 An association with increased Tn-C expression in malignant tumours and en-
hanced malignant behaviour of the disease has been established in several studies, 
Table 4.
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Table 4
Studies on the positive association between increased Tn-C expression and 
enhanced malignant behaviour of the disease. 
Author Tumour
Harada et al. 1994 oral squamous cell carcinoma
Jahkola et al. 1996 breast cancer
Jahkola et al. 1998 breast cancer
Tanaka et al. 2000 osteosarcoma
Aishima et al. 2003 intrahepatic cholangiocarcinoma
Leins et al. 2003 brain tumours
Koljonen et al. 2005 Merkel cell carcinoma
 A study on 52 astrocytic brain tumours reported a correlation between Tn-C 
expression in tumour vessels and the tumour network and the degree of histological 
malignancy. It was suggested that Tn-C in tumour vessels was produced either by the 
tumour cells or by the vascular components with the induction of the surrounding 
tumour cells. These fi ndings associated Tn-C with neoplastic angiogenesis (Kim et al. 
2000). 
 Contradictory fi ndings report that in malignant salivary gland tumours (Karja et 
al. 1995), the majority of the tumours were Tn-C-negative and that Tn-C immuno-
reactivity was not associated with the clinical behaviour of these tumours. In clini-
cal reports of invasive breast cancer and colon cancer, patients with Tn-C positive 
tumours have had a better prognosis than those with Tn-C negative tumours (Shoji et 
al.1993, Iskaros et al. 1997). 
 In clinical practice, Tn-C has been used in therapeutic studies of malignant glio-
mas. In a phase I trial, newly diagnosed patients with malignant gliomas but with no 
prior radiation therapy or chemotherapy were treated with a single injection of 131I 
radiolabelled anti-Tn monoclonal antibody administered clinically into surgically cre-
ated resection cavities. The results have been encouraging in respect of the survival of 
the patients, the toxicity of the therapy and the prevalence (only 2.5%) of debulking 
surgery for symptomatic radiation necrosis (Cokgor et al. 2000). 
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2.9. Ezrin
Ezrin, radixin and moesin constitute the ERM (ezrin-radixin-moesin) intracellular 
protein family (Berryman et al. 1993, Tsukita et al. 1997, Vaheri et al. 1997), which is 
known to mediate an interaction between actin microfi laments and cell membranes. The 
proteins are thought to play a key role in the control of cell morphology (Vaheri et al. 
1997, Hiscox and Jiang 1999). Members of the ERM family appear to have three struc-
tural domains: N-domain, α-domain and C-domain with a high percentage (72–75%) of 
amino-acid sequence homology. Merlin (or schwannomin), a tumour suppressor protein 
defective or absent in schwannomas and meningeomas and mutated in neurofi bromatosis 
2, is a diverged member of the ERM family, having only 49% identical protein structure 
(Louvet-Vallee 2000). The functional properties of merlin are thus considered to differ 
somewhat from those of ERM proteins. The ERM proteins each exhibit both a tissue-
specifi c expression pattern in the whole body and a restricted pattern of expression. Ezrin 
is expressed in a wide variety of epithelial and mesothelial cells, e.g. at high levels in the 
small intestine, stomach, lung, pancreas and kidney (Gould et al. 1989, Berryman et al. 
1993). The ERM proteins are concentrated in actin-rich surface structures just beneath 
the plasma membrane; ezrin is specifi cally localised in microvilli and in membrane ruf-
fl es (Berryman et al. 1993). 
 Ezrin, the best studied member of the ERM family, is a 70kDa phosphoprotein 
purifi ed in 1983 (Bretscher 1983). Like the other ERM proteins, ezrin exists in two 
forms: an active state that is localised beneath the plasma membrane, and a dormant 
state that is soluble in the cytoplasm. The tyrosine phosphorylation of a C-terminal 
residue of ezrin is mediated by the Rho pathway and induced by several growth fac-
tors, e.g. EGF and HGF/Scatter factor (Vaheri et al. 1997, Hiscox and Jiang 1999). 
Phosphorylation of ezrin induces transition of the protein from an inactive to an ac-
tive form (Krieg and Hunter 1992). 
 Ezrin binds actin fi laments by their C-terminal domains, and cell surface adhe-
sion molecules such as CD43 and CD44, ICAM-1, -2, -3 and syndecan 2 by their 
globular N-terminal domains (Kaul et al. 1996, Heiska et al. 1998). As well as acting 
as a structural linker between the plasma membrane and the actin cytoskeleton, ezrin 
is believed to relay signals between the surface and the interior of the cell. Ezrin is 
also suggested to be involved in cell-cell and cell-substrate adhesion events (Hiscox 
and Jiang 1999) and in microvilli formation (Takeuchi et al. 1994, Kaul et al. 1996). 
Microvilli furthermore are considered to play an important role in the early step of 
tumour invasion (Weiss 1976). Microvilli have been demonstrated to disappear from 
the cell surface of thymoma cells when cultured in the presence of antisense oligo-
nucleotides, which suppress expression of ERM proteins. This leads to the destruc-
tion of cell-cell and cell-substrate adhesion (Takeuchi et al. 1994), as was noted in 
colorectal cancer cell lines, too (Hiscox and Jiang 1999). These observations provide 
further evidence of the role of ezrin in cell motility (Hiscox and Jiang 1999).
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 The ERM proteins merlin and moesin have been demonstrated to act as tumour 
suppressors. A defi ciency of merlin encoding neurofi bromatosis 2 was associated with 
the development of a variety of cancers and a high rate of metastasis (McClatchey 
2003). The immunoreactivity of moesin was diminished in metastatic lesions in the 
skin and lymph node of melanoma (Ichikawa et al. 1998). In contrast to these fi nd-
ings, other studies indicate an active role for ezrin in promoting cell growth, inva-
siveness and metastasis. In vitro studies suggest that expression of ezrin in cell lines 
of endometrial (Ohtani et al. 1999), pancreatic (Akisawa et al. 1999) and colorectal 
carcinoma (Hiscox and Jiang 1999) plays a role tumour cell morphology, invasion 
and migration. 
 In a mouse rhabdomyosarcoma, ezrin expression correlated signifi cantly with 
metastasis (Yu et al. 2004). The same was discovered in a mouse model of osteosar-
coma, where suppression of ezrin reduced lung metastases in mice (Khanna et al. 
2004). In a clinical study on dogs with osteosarcoma, the presence of strong ezrin 
expression was associated with shorter disease-free intervals than in dogs with low 
expression of ezrin in primary tumours (Khanna et al. 2004). Similarly, in a study 
on paediatric patients with osteosarcoma, strong ezrin expression in primary tumours 
was associated with shorter disease-free intervals than in patients showing low ezrin 
expression (Khanna et al. 2004). In a small group of paired primary and metastatic 
lesions of endometrial cancers, expression of ezrin was higher in metastatic than in 
matched primary samples (Ohtani et al. 2002). In astrocytic tumours of the brain, 
an increase in ezrin immunoreactivity correlated with increased malignancy of the 
tumours (Geiger et al. 2000). In a study of uveal melanoma, two-thirds of the speci-
mens were immunoreactive for ezrin. The presence of ezrin immunoreactivity was 
associated with higher mortality and with two independent high-risk characteristics: 
microvascular density and number of macrophages in tumours (Mäkitie et al. 2001). 
In serous ovarian carcinomas, in contrast to other previous reports, negative or weak 
immunoreactivity correlated with poor patient outcome (Moilanen et al. 2003).
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AIMS OF THE STUDY
The prognosis of primary melanoma is good if it is diagnosed at an early phase and 
treated radically. Once the tumour has metastasised, the prognosis deteriorates and no 
specifi c curative treatment is available. The established prognostic factors do not always 
identify the high-risk patients who should be followed up intensively and selected for 
adjuvant therapies. The main purpose of this study was to identify tumour-related mark-
ers for predicting the behaviour of primary melanoma and to evaluate the prognosis for 
melanoma patients in a clinical series of the Finnish population.
The specifi c aims of the study were: 
1. To defi ne the overall prognosis of melanoma in a series of patients treated and 
followed up in a single unit to evaluate patient- and tumour-related prognostic 
factors for survival (Study I) 
2. To investigate the expression and prognostic signifi cance of Ki-67, Bcl-2 and 
p53 in primary melanoma and to analyse the behaviour of these markers during 
disease progression (Study II) 
3. To examine the role of tumour vascularisation as a prognostic factor in primary 
melanoma (Study III)
4. To evaluate the expression patterns and prognostic signifi cance of tenascin-C in 
primary melanoma (Study IV) 
5. To explore the expression of ezrin in primary melanoma and to assess its 
correlation with the course of the disease (Study V)
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MATERIALS AND METHODS
1. Patients (Studies I-V)
The subjects in Study I consisted of all patients diagnosed with primary melanoma and 
registered as primary melanoma patients at the Department of Plastic Surgery, Helsinki 
University Hospital, Helsinki, Finland, between 1998 and 1991. Eight of the original 306 
patients were excluded because re-examination of their tumours did not confi rm the di-
agnosis, leaving 298 patients to form the entire patient population in Study I. Subgroups 
of patients for Studies II-V were selected from the patient population in Study I on the 
basis of the concurrent availability of tumour blocks, and consisted partly of the same 
patients. The disease history and the clinical data on patient characteristics and surgical 
treatment and on consultations and treatments by oncologists were gathered from the 
patients´ records.
 The patients were followed up postoperatively at 3-month intervals for the fi rst 
2 years, and thereafter every 6 months for up to 5 years. Special attention focused 
on the surgically treated area and the lymph nodes and on any suspicious skin le-
sions elsewhere in the body. Radiological examinations and fi ne-needle biopsies were 
conducted on the basis of the clinical status. The fi nal status was determined after a 
prospective clinical follow-up investigation and established whether the patient was 
disease-free, had developed recurrences or metastases or had died of melanoma. The 
data were collected from the patients´ records. The overall survival data indicating 
whether the patient had died of melanoma or of some other cause, or was still alive 
were obtained from the National Population Registry. The study was approved of by 
the Ethics Committee of the Department of Surgery, Helsinki University Hospital.
2. Tumours (Studies I-V)
The tissue samples were collected from various pathology laboratories, the majority of 
them located in Southern Finland. The immunohistochemical studies (II-V) were con-
ducted on all tumours from the original material (Study I) that were currently available. 
The samples were re-examined by an expert pathologist to verify the melanoma diag-
nosis. The Breslow and Clark classifi cations were also re-assessed. The tumours were 
classifi ed according to the 1992 AJCC staging system in classifying the tumours, Table 
5. During the period in which the primary melanomas were re-examined, the presence 
of ulceration was not a major criterion for staging melanomas. This was not therefore 
systematically re-analysed and so the number of ulcerative tumours may have been un-
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derestimated. At the time of our study the technique of detecting nodal micrometastases 
by examining the sentinel nodes was not yet in use. The data on patients and tumours 
in individual studies are presented in Table 6. The fi rst metastatic tissue specimen of 12 
patients was also analysed in Study V, and of 18 patients in Study II; these tissue sam-
ples were collected from the Department of Pathology, University of Helsinki, Helsinki, 
Finland. The metastatic samples were of local recurrent tumours of the skin (n = 4) and 
subcutis (n = 6) and of regional lymph node metastases (n = 8). 
Table 5
Staging system for cutaneous melanoma according to AJCC in 1992
Criteria TNM AJCC
tumour thickness ≤ 0.75 mm 
and/or Clark level IIa
pT1N0M0 IA
tumour thickness 0.76-1.5 mm 
and/or Clark level III
pT2N0M0 IB
tumour thickness 1.51-4 mm 
and/or Clark level IV
pT3N0M0 IIA
tumour thickness > 4 mm 
and/or Clark level V
pT4N0M0 IIB
Limited regional nodal 
metastases or fewer than fi ve 
in-transit metastases
any pT,N1,M0 III
Advanced regional metastases 
or systemic metastases
any pT,N2,M0 or
any pT, any N, M1 or M2
IV
aWhen tumour thickness and level of tumour invasion (Clark classifi cation) do not 
coincide within the pT classifi cation, thickness should be given precedence. 
44
Materials and methods
Table 6
Patient and tumour data (Studies I to V)
Parameter Study I
n = 298
Study II
n = 117
Study III
n = 84
Study IV
n = 98
Study V
n = 95
Prospective, clinical 
follow-up, median 
years (range) 
4.8
(0.03-9.3)
4.6
(0.2-7.5)
4.05
(0.2-7.5)
3.9
(0.04-7.4)
4.8
(0.2-10.0)
Overall follow-up, 
median years (range) 
9.5
(0.1-12.5)
10.0
(8.6-15.6)
4.05
(0.6-7.5)
9.3
(0.5-12.1)
9.1
(0.5-15.4)
Age at diagnosis, 
median years (range)
53.9
(17.0-88.2)
54.5
(24.0-88.0)
54.2
(20.8-88.2)
57.4 
(24.0-84.6)
58.6
(24.0-84.6)
Male/Female 161/137 59/58 42/42 47/51 44/51
Tumour thickness, 
median mm (range) 
1.2
(0.2-20.4)
1.2
(0.3-10.0)
1.2
(0.4-7.0)
1.0
(0.3-7.0)
1.2
(0.4-15.6)
Tumour invasion: 
Clark I
Clark II
Clark III
Clark IV
Clark V
Unclassifi ed
16
36
123
97
11
15
0
7
66
38
5
1
0
3
51
25
4
0
6
8
56
24
3
0
1
7
50
32
4
1
Tumour ulceration: 
present
absent
34
264
16
101
14
70
14
84
15
80
Tumour location: 
Head or neck
Trunk
Upper extr.   Lower 
extr.
Palm
Sole of foot
Vulva
Perineum
38
115
46
78
5
10
4
2
12
47
19
31
2
5
1
10
35
13
20
2
3
1
12
40
16
25
1
4
0
11
36
17
27
1
3
0
Recurrent disease:
yes
no
73 (24%)
225 (76%)
34 (29%)
83 (71%)
17 (20%)
67 (80%)
19 (19%)
79 (81%)
26 (27%)
69 (73%)
Cause of death:
Melanoma
Other
53 (18%)
46 (15%)
22 (19%)
20 (17%)
9 (11%)
1 (1%)
11 (11%)
18 (18%)
16 (17%)
20 (21%)
Alive 199 (67%) 75 (64%) 74 (88%) 69 (71%) 59 (62%)
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3. Immunohistochemistry (Studies II–V)
 
Immunohistochemistry for detection of Ki-67, Bcl-2, p53 (n=117), CD-31 (n=84), and 
for tenascin-C (n=98) was performed at the Haartman Institute Laboratory, University 
of Helsinki and for ezrin (n=95) at the Laboratory of Pathology and Anatomy and 
Neuroscience Program, Biomedicum, University of Helsinki. 
 Sections 5µm thick were cut from paraffi n-embedded tissue blocks, deparaffi nised 
and rehydrated. The sections were pretreated for Ki-67, Bcl-2 and p53 with 10 mM 
sodium citrates buffer pH 6.0 in a microwave oven for 4x5 min and left in the buffer 
at room temperature for 20 min, and for ezrin with 10 mM sodium citrate buffer 
pH 6.0 at 95◦C for 10 min. The sections were subjected to enzymatic digestion with 
Protease XXVIII (1mg/ml of phosphate buffered saline (PBS) at 37◦C for 7 min) in 
the procedure for CD-31 and with pepsin (0.1% in 0.01 M HCl at 37
◦C for 30 min) 
for Tn-C. After antigen retrieval, the slides were incubated with primary antibodies. 
Binding of the primary antibodies was detected with specifi c secondary antibodies 
according to each manufacturer´s instructions. The sections were then counterstained 
with haematoxylin, Table 7. 
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Table 7
Immunohistochemistry
Antigen Monoclonal 
Antibody Dilution
Immunoperoxidase 
technique Study
Ki-67     Mib-1 
Immunotech. 
Marseilles
France 
1:500      VECTASTAIN® Elite 
ABC Kit, Vector 
Laboratories, Inc. 
Burlingame, CA, USA
II and V
Bcl-2     anti-Bcl-2
DAKO 
Glostrup
Denmark
1:200      VECTASTAIN® Elite 
ABC Kit, Vector 
Laboratories, Inc. 
Burlingame, CA, USA
II and V
p53     anti-p53
DAKO
Glostrup
Denmark 
1:300       VECTASTAIN® Elite 
ABC Kit, Vector 
Laboratories, Inc. 
Burlingame, CA, USA
II and V
CD-31   
 
JC/70
DAKO
Glostrup
Denmark
1:50       DAKO 
StreptABComplex/
HRP Duet Mouse/
Rabbit Kit Glostrup
Denmark
III 
Tn-C 143DB7
Biohit 
Diagnostics 
Oy, Helsinki 
Finland
1:2000 alkaline phosphatase-
coupled rabbit 
immunoglobulins to 
mouse IgG, Dakopatts 
Glostrup, Denmark
IV
ezrin    clone 3C12 
Vaheri
Finland   
1:2000   ABC method, 
UltraVision, Lab 
Vision Inc., Fremont 
CA,USA
V
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3.1. Quantifi cation of immunohistochemistry (Studies II-V)
All immunohistochemical evaluations were performed blindly, without reference to 
the clinical data of the patients. The slides were scored independently by Ilmonen and 
Hernberg in Study II, Tarkkanen providing consultation assistance; by Ilmonen in Study 
III, Kariniemi providing consultation assistance; by Ilmonen, Turunen and Jahkola in 
Study IV; by Ilmonen and Carpen in Study V. 
 For Bcl-2, a cytoplasmic staining pattern was evaluated. The whole tumour area 
was examined, and the result was reported as the percentage of positively stained tu-
mour area. In addition, the expression pattern of Bcl-2 was scored as absent, focal or 
diffuse. If focal, immunoreactivity was present only in scattered aggregates of cells; 
if diffuse, immunoreactivity extended throughout the tumour. Epidermal basal cells 
around the tumour in adjacent normal skin and small reactive peritumoral lympho-
cytes provided the positive control.
 For Ki-67 and p53, a nuclear staining pattern was evaluated. In a tumour with 
heterogeneous Mib-1 or p53 immunoreaction, the spot in the tumour area that resem-
bled the rest of the tumour was selected for analysis. The proportion of positive cells 
among 200 tumour cells was reported. Epidermal basal cells around the tumour in 
adjacent normal skin served as the positive control. 
 For the immunostaining of CD-31, the tumour area was defi ned with the 
AxioHOME morphometric system. Because tumours showed a heterogeneous distri-
bution of vessels, an attempt was made to cover the whole tumour or most of the 
tumour area. The number of intratumoral vessels in a defi ned tumour area was then 
counted to obtain the blood vessel density. Blood vessel quantifi cation was performed 
with light microscopy. The criteria for separate countable vessels were the presence 
of a vessel lumen and any red staining cells clearly separated from adjacent vessels, 
tumour cells and connective tissue elements. Cells staining red in the presence of a 
vessel lumen in the adjacent normal dermis served as the positive control, Figure 1.
 For Tn-C, both extracellular expression in the stroma and cytoplasmic staining 
patterns were evaluated. The stromal expression of Tn-C for was scored either as 
negative or as focally or diffusely positive. The staining pattern was scored as focal if 
there were both Tn-C-positive areas and completely Tn-C-negative areas in the sec-
tion of tumour examined, and as diffuse if the entire part examined was fi lled with 
tenascin. Beneath the basement membrane, a diffuse staining pattern was seen as a 
continuous band of Tn-C. In the stroma of the tumour, diffuse Tn-C appeared as a 
dense network around melanoma islets; and in the stroma of invasive regions diffuse 
Tn-C expression was seen as a continuous thin border. Cytoplasmic staining of Tn-C 
was either positive or negative. Epidermal basement membrane in adjacent normal 
skin served as the positive control, Figures 2a and b.
 For ezrin, a cytoplasmic staining pattern was evaluated. Immunoreactivity was 
graded as negative, weak or strong. The colour intensity in the positive immunoreaction 
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determined whether the classifi cation was weak or strong. The immunoreaction tended 
to be homogeneous throughout the tumour, with the few exceptions of tumours with 
varying intensity in different regions of the tumour. In these cases, a higher staining 
intensity in more than 20% of cells was classifi ed in the higher category. Epithelial 
cells of the surrounding normal skin and the peritumoral lymphocytes served as the 
positive control, Figures 3a and b.
 Negative controls for all studies were provided by omitting the primary antibodies 
and substituting irrelevant monoclonal antibodies. 
4. Statistical analysis (Studies I-V)
Statistical analyses were performed with the Statview™ statistical program (Abacus 
Concepts Inc., Berkeley, CA, USA). Melanoma-related disease-free survival time was 
calculated as the time interval between diagnosis and the fi rst recorded sign of disease 
progression after the primary operation. Melanoma-related overall survival was defi ned 
as the time interval between diagnosis and death from melanoma. Patients with no signs 
of progression at their last follow-up visit and patients who died of other causes were 
censored at the time of their last visit or death, respectively. 
 The distribution of parameters was characterised by standard descriptive methods. 
Contingency tables were analysed by chi-square test and Fisher´s exact test. The non-
parametric Mann-Whitney U test, Kruskall-Wallis test and Spearman rank correlation 
test were used to analyse nonparametric variables. Multiple regression analysis was 
applied to show the diminishing of surgical margins during 1988-1991 in Study I. 
The Wilcoxon signed rank test was used to compare the values of Ki-67, Bcl-2 and 
p53 in primary and metastatic tumours in pairs. Univariate analysis of disease-free 
and disease-specifi c overall survival was based on the Kaplan-Meyer method, and 
differences in survival were tested with the Mantel-Cox (log-rank) test. Independent 
prognostic factors were identifi ed with stepwise Cox multivariate analysis. p values 
‹ 0.05 were considered statistically signifi cant in Studies I, II, III and IV, and ≤ 0.05 in 
Study V. Figure 8 presents data as a box plot in which each box is composed of fi ve 
horizontal lines that display the 10th, 25th, 50th (median), 75th and 90th percentiles of a 
variable such that the central 50% of the values falls within the range of the box. The 
central vertical lines in the boxes mark the medians. Values above the 90th and below 
the 10th percentile are plotted as points. 
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Figure 1
Rich vascularity associated with 
primary cutaneous melanoma 
visualised by endothelial immuno-
histochemical staining of CD-31.  
Figure 2
Tenascin-C immunoreactivity in 
primary melanoma specimens. 
Examples of tumours showing 
a) diffuse Tn-C expression at the 
upper dermal lateral border 
(thick arrow) and at the deep, 
dermal border (thin arrow) 
in a superfi cial melanoma;
b) diffuse Tn-C expression in the 
tumour stroma forming a net-
work around melanoma islets.
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Figure 3
Ezrin immunoreactivity in primary melanoma specimens. Examples of tumours 
showing  a) weak ezrin immunoreactivity in the stroma;
b) strong ezrin immunoreactivity in the stroma. 
Note also strong immunoreactivity of tumour-associated lymphocytes 
in a) and b). 
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RESULTS
1. Study I
Most of the tumours (77%) had already been excised by general practitioners or surgeons 
before the patients were seen at their fi rst visit to Helsinki University Hospital. The ma-
jority of the tumours were local, 91% being stage I or II. At the spot where a melanoma 
later developed, 42% of the patients had had a nevus for several years and 10% of them 
from early childhood or birth. However, 38% of patient records made no mention of a 
pre-existing nevus. The different histories of the nevus anamnesis seemed to have prog-
nostic infl uence on survival. Melanomas arising straight from the normal skin were more 
often ulcerated (20.7%) and thicker (median tumour thickness 2.5 mm) and had a poorer 
prognosis than melanomas that had developed from a short-lived nevus. 
 The excision margins of the tumours diminished in the whole patient population 
during 1988-1991 from 5 cm median, range (0.5-7.0cm) to 2 cm median, the reduc-
tion in the excision margins following the recommendations based on the results of 
randomised trials on surgical margins at that time. 
 Regional lymph node dissections were performed on 128/298 patients, 95 (74%) 
of them being prophylactic and 33 (26%) therapeutic in their indications. The most 
common site of lymph node dissection was the axilla, 54.7%, followed by the groin, 
32.0%, and the neck, 11.7%. The remaining 1.6% consisted of supraclavicular or 
para-aortal node dissections, Table 8. 
Table 8
Tumour data (Study I)
Clinical presentation of 
tumour at fi rst hospital visit
Not operated on
Removed
Recurrence in scar
Metastatic disease
61 (20%)
230 (77%)
2 (1%)
5 (2%)
Stage of tumour at diagnosis 
(AJCC 1992)
In situ
Local
Regional lymph node 
metastasis
Distant metastasis
16 (5%)
271 (91%)
8 (3%)
3 (1%)
Nevus history prior to 
melanoma
Absent
Since early childhood or birth
For several years
No information
29 (10%)
29 (10%)
126 (42%)
114 (38%)
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The survival of the melanoma patients (n = 298) was analysed. Fifty-three (18%) 
patients died of melanoma and 46 (15%) of other causes; 199 (67%) of the patients 
were alive at the end of the follow-up period. Cumulative melanoma-specifi c overall 
survival of patients with invasive melanoma (n = 282) is shown in Figure 4.
 In univariate analysis, signifi cant prognostic markers were tumour thickness 
(Breslow classifi cation), depth of tumour invasion (Clark classifi cation), stage at di-
agnosis, tumour ulceration and age of the patient at diagnosis. Tumour location on 
the trunk was a signifi cant factor for overall survival. Tumour ulceration and tumour 
location on the trunk were adverse prognostic parameters. The survival outcome was 
better for younger than for older patients. Age of the patient is considered as a nomi-
nal parameter, the cut-off point 53.9 years representing the median value, Table 9. 
Cumulative melanoma-specific overall survival 
Figure 4
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Table 9
Prognostic factors for survival, univariate analysis (Study I)
Parameter Disease-free survival, p Overall survival, p
Tumour thickness ‹ 0.0001 ‹ 0.0001
Depth of tumour invasion ‹ 0.0001 ‹ 0.0001
Stage at diagnosis ‹ 0.0001 ‹ 0.0001
Tumour ulceration   0.0005 ‹ 0.0002
Age at diagnosis; ≤ / > median 
53.9 years
  0.04   0.04
Tumour location on trunk   ns   0.03*
Gender   ns   ns
Surgical margins   ns   ns
*analysis was stratifi ed by tumour thickness
ns = nonsignifi cant
 In Cox multivariate analysis, tumour thickness (p = 0.01) and tumour stage 
(p = 0.04) were the strongest prognostic factors for disease-free survival. Tumour 
stage (p = 0.01), tumour thickness (p = 0.02) and tumour location on the trunk 
(p = 0.03) were the strongest prognostic factors for overall survival. 
54
Results
2. Study II
2.1. Immunoreactivity of Ki-67, Bcl-2 and p53 in 
primary and metastatic tumours
Positive immunoreactivity for Ki-67 in primary melanomas was detected in 103 tumours 
but was absent in ten. Positive immunoreactivity ranged from 0% to 60% in tumour 
cells, with a median value of 9.75%, Figure 5a. In metastatic tumours the median value 
of Ki-67 immunoreactivity was slightly higher (8.3% vs 7.0%) than in primary tumours, 
but the range was wide (0-40%), including tumours lacking Ki-67 expression, Figure 5b. 
Paired (18 pairs) analysis of primary and metastatic tumours of the same patient did not 
demonstrate any consistent trend in the behaviour of Ki-67 expression.
a)                                                                    b) 
0
5
10
15
20
25
30
35
40
N
u
m
be
r o
f t
u
m
ou
rs
-10 0 10 20 30 40 50 60 70
Ki-67 expression, % of tumour cells
0
1
2
3
4
5
6
7
N
um
b
er
 o
f m
e
ta
st
a
se
s
-5 0 5 10 15 20 25 30 35 40 45
Ki-67 expression, % of tumour cells
Figure 5
Histogram of Ki-67 expression a) in primary melanomas (n = 113) and b) in 
metastatic tumours (n =18)
 Bcl-2 expression presented a wide range (0-100%) in primary tumours, with a 
median value of 70% of tumour cells expressing Bcl-2. The biggest subgroups of 
tumours were those without expression (n = 10), and those with 100% positive im-
munoreactivity for Bcl-2 throughout the tumour (n = 17), Figure 6a. The majority 
of tumours expressed Bcl-2 focally (n = 70, 67%) and 25 (24%) diffusely; 10 (9%) 
showed no expression. Bcl-2 expression showed a wide variation in metastatic tu-
mour samples, too. The range of immunoreactivity was from 0% to 100% in tumour 
cells, with a median value of 55.0%. The biggest subset constituted tumours with less 
than 10% immunoreactivity, Figure 6b. Paired sample analysis of 18 cases revealed a 
trend towards decreasing expression of Bcl-2 during disease progression (p =0.08). 
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Figure 6
Histogram of Bcl-2 expression a) in primary melanomas (n = 105) and b) in 
metastatic tumours (n = 18)
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 In primary melanomas, 49/101 (48%) of tumours expressed no p53 at all. The 
range maximum for p53 expression was 94%, with a median value of 0.25%, Figure 
7a. In melanoma metastases, 12/18 (67%) did not express p53. In the 6/18 (33%) of 
the metastases expressing p53, the level of expression was under 15%, the distribution 
shown in Figure 7b. Paired sample analysis of the 18 cases showed a trend towards 
decreasing expression of p53 during disease progression (p = 0.08). 
Figure 7
Histogram of p53 expression a) in primary melanomas (n = 101) and in meta-
static tumours (n = 18)
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2.2. Associations with clinicopathological characteristics
The Ki-67, Bcl-2 or p53 expression levels of primary melanomas were not associated 
with tumour thickness or tumour invasion level, nor did these markers show any cor-
relations with each other. Ki-67 and Bcl-2 expressions were higher in ulcerative than in 
non-ulcerative tumours (p = 0.12 and p = 0.05, respectively). Strong Bcl-2 expression 
also had associations with male gender (p = 0.04) and old age of the patient (p = 0.04).
2.3. Association with prognosis
In univariate analysis of the entire patient population, neither Ki-67, Bcl-2 nor p53 were 
prognostic factors. However, in the subgroup of intermediate tumour thickness (Breslow 
1.01 – 4.0 mm, n = 52), there was a trend towards disease-free survival and an over-
all survival benefi t for those with tumours showing low Bcl-2 expression as compared 
with those with tumours showing high Bcl-2 expression (p = 0.09 and p = 0.08, respec-
tively). The reason why the same association with prognosis was not discovered in thin 
(≤ 1 mm, n = 53) or in thick (› 4 mm, n = 11) melanomas may be due, on the one hand, 
to the small number of events (n = 4 in DFS and n = 3 in OS) in thin melanomas and, on 
the other, to the small number of patients in the thick melanoma group. The expression 
pattern of Bcl-2 between absent, focal and diffuse immunoreactivity had no correlation 
with the clinical course of the disease.
 In Cox multivariate analysis for disease-free survival, tumour thickness was the 
most important prognostic factor (p = 0.0002), and low expression of p53 indicated 
a favourable prognosis (p = 0.05). In overall survival, tumour thickness was the only 
signifi cant prognostic factor (p = 0.0006). 
 In melanoma metastasis, the level of Ki-67, Bcl-2 or p53 expression showed no 
association with the fi nal outcome of the disease. 
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3. Study III
3.1. Immunoreactivity of CD-31 and clinicopathological associations
The blood vessel density of tumours ranged from 1 to 65 vessels/mm2, with a median 
value of 20.0 vessels/mm2. Thicker tumours showed a trend towards lower vascularisa-
tion, Figure 8. 
Figure 8
Box plots of vessels detected in primary melanoma samples with different 
tumour thicknesses
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     1 = Tumour thickness ≤ 1 mm, n = 31
     2 = Tumour thickness 1.01 – 2.0 mm, n = 23
     3 = Tumour thickness 2.01 – 4 mm, n = 22
     4 = Tumour thickness › 4 mm, n = 8
Tumour vascularity did not relate signifi cantly to patient or tumour characteristics 
such as the gender or age of the patient, or the invasion level, location or ulceration 
of the tumour.
3.2. Association with prognosis
In univariate analysis of overall survival, the depth of tumour invasion (Clark classifi ca-
tion) was an independent prognostic marker (p = 0.02) and tumour vascularity was an 
important, but not an independent factor determining prognosis (p = 0.06). High tumour 
vascularity was associated with a good prognosis. In Cox multivariate analysis, tumour 
thickness was an independent prognostic factor in disease-free survival, as was the level 
of tumour invasion in overall survival. Tumour vascularity held second position in both 
disease-free and overall survival but provided no further signifi cant information. 
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4. Study IV
4.1. Immunoreactivity of tenascin-C and clinicopathological associations
The following regions of the tumours were examined by Tn-C expression: general stro-
mal expression, stromal expression at invasion fronts and intracytoplasmic expression. 
The invasion regions under examination were the intraepidermal lateral border, the up-
per dermal lateral border and the deep, dermal or subcutaneous border. 
 In general, Tn-C was widely expressed in primary melanoma samples with the 
exception of intracytoplasmic staining, which was rare (in 20% of tumours only). The 
staining pattern varied from focal to diffuse in different parts of the tumour. Only in 
two tumours was Tn-C completely absent. 
 No correlation existed between intensity of Tn-C staining and tumour thickness, 
level of tumour invasion, tumour ulceration or the number of peritumoral lym-
phocytes. Neither the gender nor the age of the patient correlated with expression of 
Tn-C. 
4.2. Association with prognosis
Absence or low expression of Tn-C in the tumour seemed to be a generally benefi cial 
prognostic sign. The absence of Tn-C expression at the intraepidermal lateral border, 
the upper dermal lateral border, the deep (dermal or subcutaneous) border of the tumour 
or in tumour stroma of melanomas was associated with better disease-free survival of 
patients than was positive staining in univariate analysis (p = 0.26, p = 0.06, p = 0.05 
and p = 0.07, respectively). Accordingly, the absence of intracytoplasmic staining was a 
benefi cial prognostic sign for disease-free survival (p = 0.04). For overall survival, the 
trends were the same but not statistically signifi cant. In multivariate Cox analysis of dis-
ease-free survival, tumour ulceration (p = 0.01) and intracytoplasmic expression of Tn-C 
(p = 0.04) were independent adverse prognostic factors; for overall survival, however, 
there were no independent prognostic factors.  
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5. Study V
Expression of ezrin was detected in most primary tumours (76/95, 80%). The ezrin im-
munoreactivity of metastatic specimens was, in general, stronger than was that of their 
primary counterparts; in six tumours the intensity of the metastatic tumour was higher 
than was that of the primary tumour, and in six tumours the intensity remained un-
changed, Table 10.
Table 10
Immunoreactivity for ezrin
Specimens Immunoreactivity for ezrin
Primary melanomas (n = 95)
19 negative
48 weak positive
28 strong positive
Metastatic samples (n = 12)
2 weak positive
10 strong positive 
5.1. Immunoreactivity of ezrin and clinicopathological associations 
The level of ezrin immunoreactivity had no association with the patient´s gender or 
age, or with tumour ulceration or location. However, it had a strong association with 
tumour thickness (p = 0.0008, Breslow classifi cation) and level of tumour invasion 
(p = 0.0004, Clark classifi cation). The number of tumours with strong ezrin immuno-
reactivity increased with increasing tumour thickness and level of tumour invasion. 
Inversely, the number of tumours with negative ezrin immunoreactivity decreased with 
increasing tumour thickness and level of tumour invasion. The proportion of tumours 
with weak positive expression of ezrin was not signifi cantly associated with tumour 
thickness. There was a correlation between higher Ki-67 expression and increased 
ezrin immunoreactivity (p = 0.04). Ki-67 had a weak correlation with tumour thickness 
(p = 0.10) and a stronger correlation with level of tumour invasion (p = 0.009); Ki-67 
being higher in thicker tumours. No correlations were found between ezrin immunoreac-
tivity and Bcl-2 or p53 expression of tumours.  
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5.2. Association with prognosis
In univariate analysis, patients without ezrin immunoreactivity had a disease-free sur-
vival benefi t (2/19, 10.5%, with metastatic disease) as compared with those with positive 
(either weak or strong) ezrin immunoreactivity (22/76, 28.9%, with metastatic disease): 
however, the difference was not statistically signifi cant (p = 0.19). For melanoma-spe-
cifi c overall survival, there were no statistical differences between patients with or with-
out ezrin immunoreactivity. In multivariate analysis for survival, ezrin immunoreactivity 
was not a prognostic factor. 
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DISCUSSION
1. Survival 
The survival of melanoma patients has continuously improved in Finland. The 5-year 
melanoma-specifi c overall survival for patients diagnosed with melanoma during 
1960–1969 was 51.1% and for 10-year survival 43.7%. The survival rates during 
1990–1999 had, however, risen to 84.6% and 84.2%, respectively (Finnish Cancer 
Registry 2005). The survival of patients with localised melanoma, in particular, has 
improved since the early 1960s. In contrast, the survival of patients with non-localised 
melanoma has improved only very slowly during the same time period, the 5-year 
rate for patients with non-localised melanoma still being below 30% (Finnish Cancer 
Registry 2005). The fi rst clinical study of a Finnish melanoma population and its survival 
was that of Brandt in 1956 (Brandt 1956). Half of the patients (49.7%, n = 112) already 
had regional or distant metastases at diagnosis, and the 5-year overall survival rate was 
only 20.5%. Later, in 1977, in the study of Pakkanen on a Finnish melanoma population 
(n = 691), 75% of men´s and 80% of women´s tumours were stage I at diagnosis, and 
the 10-year survival rate was 41% for men and 53% for women (Pakkanen 1977). 
Karjalainen et al. (1998) reported a crude 5-year survival rate of 78% for a Finnish series 
of 369 localised cutaneous melanoma patients between 1974 and 1989.
 Our study comprised all the primary melanoma patients that were diagnosed or 
treated at the Department of Plastic Surgery, Helsinki University Hospital during 
1988-1991. The clinical follow-up data were gathered from patients´ records, and the 
overall survival data indicating whether the patient had died of melanoma or of some 
other cause or was still alive were obtained from the National Population Registry. 
The reliability of the registry is considered good, although it should be noted that 
some information on the cause of death is probably lacking as post mortem examina-
tions were not performed systematically on all mortalities. Further it should be noted 
that in the retrospective approach of this study we lacked the standardisation of treat-
ments and follow-up as in retrospective studies in general (Altman and Lyman 1998). 
 Tumours were mostly localised melanomas (91%). In the whole patient popula-
tion, the melanoma-specifi c 5-year overall survival rate was 85.7%, the 10-year OS 
rate 82.1%, and the 14-year OS rate 63.7%. The melanoma-specifi c 10-year OS rate 
for stage I patients (n = 153) was 92.6%, for stage II (n = 134) 72.0%, and for stage 
III (n = 8) 37.5%. Those diagnosed at stage IV (n = 3) died of melanoma within a 
few months of diagnosis. In the whole series, there were 110 (36.9%) patients with 
thin (≤ 1 mm) melanomas. Five (4.5%) of them developed metastases and, of them, 
three (2.7%) died of melanoma during the follow-up. Localised melanoma thus ac-
counts for a high proportion of all diagnosed melanomas, and the survival rates of our 
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patient population are close to those documented in the Finnish Cancer Registry dur-
ing the same time period. 
2. Prognostic factors
Until now the most important prognostic factors have been parameters describing mor-
phological characteristics of the tumour such as thickness, ulceration and invasion level. 
Additional prognostic information has been derived from patient characteristics such as 
gender, age and tumour localisation. The same classical parameters were also found to 
be important in our clinical study. Our fi nding of an association between melanomas 
arising de novo and an unfavourable prognosis should be regarded critically. Melanomas 
can grow slowly at the beginning and be neglected by patients until they have reached a 
symptomatic rapid growth phase. 
 The aim of primary surgery is to ensure local control of the disease. Very wide 
margins have not been shown to enhance prognosis (Veronesi et al. 1988, Balch et 
al. 1993, Cohn-Cedermark et al. 2000, Khayat et al. 2003, Thomas et al. 2004). Our 
study was performed at a time when a switch was being made from wide to nar-
rower surgical margins. Our fi ndings did not reveal any prognostic infl uence in the 
diffe rence in surgical margins used, although the statistical power of our study, due to 
its relatively small patient population and its retrospective nature, is not suffi cient to 
detect small differences in survival. As our study demonstrates, elective lymph node 
dissections in thick melanomas, especially in those located close to the axilla, groin 
or neck, were routinely performed until the early 1990s. The effi cacy of these prophy-
lactic lymph node dissections was long controversial, the procedure being associated 
with substantial morbidity. Recent randomised trials have shown no survival benefi t 
in the prophylactic dissection of regional lymph nodes (Cascinelli et al. 1998, Balch 
et al. 2000, Lens et al. 2002).
 In 1992, sentinel lymph node (SLN) biopsy (Morton et al.1992) was proposed 
as a minimally invasive procedure that could serve as an accurate staging method 
for primary melanomas carrying low morbidity for patients. The prognostic value of 
determining SLN status has been demonstrated in many studies (Statius Muller et al. 
2001, Doting et al. 2002, Leong et al. 2005, Yee et al. 2005). We still lack evidence 
that removal of SLN and dissection of the regional node basin if micrometastatic 
melanoma is found improve overall survival. The results of ongoing multicentre trials 
will soon answer these questions (Morton et al. 2005). 
 A number of immunohistochemical, serological and molecular markers have been 
investigated for their prognostic value but none has so far succeeded in overcoming 
tumour thickness. A single mutated gene may not explain the biological character of 
melanoma since the process of malignant transformation is highly complicated. There 
is a great need for research on melanoma cells and factors related to their metastatic 
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potential; equally important would be research focusing on interactions in the ma-
lignant stroma. Evaluation of histological tumour markers in clinical patient series 
provides a means of understanding their possible role in the spread of cancers. 
 In our studies, we concentrated on the following parameters in our search for new 
prognostic information: Ki-67, Bcl-2 and p53, tumour vascularity, and expressions of 
the proteins tenascin-C and ezrin. 
2.1. Ki-67
 
We found that expression of Ki-67 in primary melanoma samples was present in most 
tumours (103/113), the remaining tumours showing no Ki-67 expression. A cut-off point 
often used for Ki-67 immunopositivity of melanomas is 20% to distinguish tumours 
with a low proliferation rate (‹20%) from those with a high proliferation rate (≥ 20%) 
(Ramsay et al.1995a, Hazan et al. 2002). On that basis, only 17/113 (15%) of tumours 
in our series were highly proliferating, the level of positive immunoreactivity for Ki-67 
presenting rather low, with a median value of 9.7% of the tumour cells. We found that 
the level of Ki-67 immunoreactivity did not relate to tumour thickness, in contrast to 
fi ndings presented elsewhere (Moretti et al. 1990, Rieger et al. 1993, Hazan et al. 2002). 
Our tumour entity comprised mainly thin melanomas, 53/113 (45%) being ≤ 1 mm thick; 
only 11/113 (9%) were › 4 mm. This may explain the dearth of statistics showing a cor-
relation between proliferation and tumour thickness, if such existed. Ki-67 expression 
was higher in ulcerative than in non-ulcerative tumours, but the correlation did not reach 
statistical signifi cance. The association is of interest as the adverse impact of ulceration 
on prognosis in primary melanoma has now been verifi ed (Balch et al. 2001a).
 Ki-67 immunoreactivity was not a prognostic factor in our study, even if sepa-
rately examined in different subsets of tumour thickness. The prognostic value of 
Ki-67 expression in melanomas is an unsettled issue, with the strongest associations 
being revealed in thick melanomas (Ramsay et al. 1995a, Boni et al. 1996, Vogt et al. 
1997). In thin melanomas, the category to which the majority of our tumours belong, 
other, more powerful determinants most likely direct the course of the disease. 
 In metastatic specimens, the level of Ki-67 expression ranged from completely 
negative to 40% of positive immunoreactivity of tumour cells. In the paired analysis 
of primary and metastatic tumours of the same melanoma patients (n = 18), Ki-67 im-
munoreactivity increased in ten, remained unchanged in one and decreased in seven 
pairs during disease progression. This leads us to speculate that the amount of prolif-
erative cells is not crucial for the metastatic capacity of the tumour. 
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2.2. Bcl-2    
Bcl-2 was widely expressed (95/105, 91%) in our series of primary melanomas. The same 
has been discovered by other investigators of primary melanomas (Cerroni et al. 1995, 
Tron et al. 1995, Grover and Wilson 1996). Bcl-2 expression was not a prognostic factor 
in our study population, which included patients with a wide range of tumour thickness 
(Breslow 0.3-10 mm). In the subgroup of tumours of intermediate thickness (Breslow 
1.01-4.0 mm, n = 52), however, Bcl-2 expression did provide prognostic information as 
patients with tumours showing low Bcl-2 expression demonstrated a trend towards fa-
vourable survival as compared with those with tumours showing high Bcl-expression.   
 Earlier incongruent results (van den Oord et al. 1994, Ramsay et al. 1995b, Tron 
et al. 1995, Grover and Wilson 1996) of the association of Bcl-2 expression with 
melanoma progression and prognosis are a subject for speculation. Low expression of 
Bcl-2 in primary or metastatic melanomas, or both, might be explained by acquired 
autonomous growth properties of the more malignant lesions, which would therefore 
reduce the physiological requirement for Bcl-2 to maintain the anti-apoptotic capacity 
of melanoma cells. Genetic alterations are suggested to decrease the dependence on 
Bcl-2 for cell survival, other anti-apoptotic genes playing a major role. 
 Our results for decreasing Bcl-2 expression in metastatic specimens support a 
recessive role of Bcl-2 in metastatic tumour growth. In contrast, a study by Grover 
and Wilson (1996) reported the maintenance of Bcl-2 expression and its association 
with a poor prognosis of metastatic melanoma. Moreover, the melanoma metastases 
of patients not responding to chemotherapy have been reported to express particularly 
high levels of Bcl-2 protein, supporting the concept of Bcl-2 as a key regulator for 
chemotherapy-triggered apoptosis in malignant melanoma (Vlaykova et al. 2002, 
Hakansson et al. 2003). There are studies that report promising results with Bcl-2 an-
tisense therapy for melanoma patients, especially in combination with chemotherapy 
(Jansen et al. 1998, Jansen et al. 2000). It is known that susceptibility to apoptosis 
depends on tumour type (Staunton and Gaffney 1995); the role of Bcl-2 may also be 
tumour specifi c. Our fi ndings indicate an adverse character for high Bcl-2 expression 
in primary melanoma. It is hoped that future studies will clarify the value of Bcl-2 as 
a predictive marker, and also its possible use in immunotherapy. 
2.3. p53
 
We discovered that the immunohistochemical detection of p53 in primary melano-
mas was low, with 49% of tumours completely negative for p53 expression. 
Immunohistochemical staining can detect the p53 protein in only very small amounts 
in the normal skin (Lane and Benchimol 1990). Most studies report the absence of p53 
expression in melanocytic nevi (Radhi 1999, Sauder 1999). In primary melanomas, p53 
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gene mutations are rare, amounting to less than 5%. However, the frequency of positive 
immunoreactivity differs (0-66%) among different studies (Florenes et al. 1994, Lee et 
al. 1995, Radhi 1999, Sauder 1999). In some internal cancers, e.g. colorectal and lung 
cancers, concordance exists between the presence of p53 gene mutations and expression 
of the p53 protein in immunohistochemistry (Rodrigues et al. 1990, Bodner et al. 1992). 
In melanomas, in contrast, no such relationship exists, indicating that not all immuno-
histochemically detectable p53 expression is due to the presence of gene mutations but 
rather is a sign of disturbed cellular processes (Florenes et al. 1994, Akslen et al. 1998). 
In our series of metastatic samples, p53 expression was even more rare and the majority 
of tumours (67%) did not express it at all. Results for the presence of p53 gene muta-
tions in metastatic tumours vary in different studies ranging from 9% (Zerp et al. 1999) 
to 23% (Florenes et al. 1994) and to 70% of tumour cells (Sparrow et al. 1995).
 Our fi ndings of no association between p53 expression and tumour thickness in 
primary melanomas and the strongly reduced expression of p53 in metastases imply 
that p53 expression is an early event in tumour progression. In multivariate analysis 
for disease-free survival of patients with primary tumours, high expression of p53 
was an independent adverse prognostic factor. Thus high p53 expression in primary 
melanomas may be associated with altered cell cycle regulation and thus have an ef-
fect on the course of the disease. 
 p53 mutations occur at a much lower frequency in primary melanomas than they 
do in non-melanoma skin cancers or any carcinomas, and the role of these mutations 
in melanocytic tumours is still unclear. Expression of p53 can obviously not be used to 
discriminate between benign and malignant melanocytic tumours, and the prognostic 
value of p53 in primary melanoma will have to be determined in further investigations. 
2.4. Tumour angiogenesis 
We discovered that tumour vascularisation was inversely associated with tumour thick-
ness. The most richly vascularised tumours were found among the thinnest (‹ 1.0 mm) 
tumours, whereas vascularisation was lower in intermediate thickness (1.0–4.0 mm) and 
thick (> 4 mm) tumours. The subgroup of thick tumours was the smallest, comprising 
only eight cases. However, there was no association between tumour vascularisation 
and the level of tumour invasion level (Clark classifi cation), this parameter probably not 
being suffi ciently accurate to distinguish the thinnest tumours from others. By anatomi-
cal localisation, the most highly vascularised tumours were in the lower extremities, in 
the palm and sole of the foot, although the number of tumours in those regions was 
restricted to a couple of cases. Controversially, in the region of the head and neck, where 
there is abundant vascularity of the skin, tumours were the least vascularised. These fi nd-
ings lead us to propose that the vascularity of the tumour is not related to the vascularity 
of the surrounding skin; rather it is an intrinsic character of the tumour. There was no 
66
Discussion
relevant association between tumour vascularity and the presence or absence of tumour 
ulceration. The mechanisms behind the formation of ulceration of the overlying epider-
mis of the tumour are unclear; our fi ndings suggest, however, that tumour vascularity is 
not a contributing factor. 
 From the prognostic viewpoint, melanoma patients with highly vascularised 
tumours had an overall survival benefi t as compared with those with sparsely vas-
cularised tumours. As tumour vascularisation was not signifi cantly associated with 
tumour thickness, there has to be some other explanation for this result. The upper 
part of healthy skin is more highly vascularised than the deeper parts, and our immu-
nohistochemical technique was not able to distinguish pre-existing vessels from the 
intratumoral vessels formed by tumour angiogenesis. Furthermore, it has been shown 
that many tumours induce a peritumoral vascular plexus that is the result of tumour 
angiogenesis, just like the tumoral vessels. This plexus may have a stronger impact on 
overall vascular counts in thin melanomas than it does in thicker and larger tumours. 
 The discrepancies between studies regarding the importance of angiogenesis in 
melanoma progression and metastasis may have arisen due to the use of patient popu-
lations not matched for clinical factors that might infl uence metastasis. Factors such 
as the capacity of a tumour for vascular invasion, the ability of a tumour to evade the 
immune system and the immunocompetence of the host may also vary. These cannot 
be standardised in prognostic studies, thus making it more diffi cult to evaluate the 
precise role of tumour vascularity. The differences in results may also be due to the 
range of methods applied for microvessel staining and for quantifying angiogenesis. 
Besides microvessel count and vascular density, other parameters including quantifi -
cation of vessel area, microvessel branching and distinct vascularisation patterns have 
been assessed and analysed in relation to prognosis (Massi et al. 2002). 
 As well as immunohistochemisty, methods such as colour Doppler sonography 
have been used in detecting intratumoral vessels (Lassau et al. 2002). Elevated ex-
pressions of several angiogenic factors, including VEGF, bFGF, and IL-8, have been 
detected in primary cutaneous melanoma, and the importance of these mediators in 
promoting melanoma angiogenesis, metastasis and survival has been confi rmed in 
tumour xenotransplant models and in clinical studies (Ugurel et al. 2001, Streit and 
Detmar 2003). Mouse model systems and clinical studies have been performed to 
evaluate the effi cacy of angiogenesis inhibition with several types of molecules in 
melanoma (Kuenen et al. 2003, Reisfeld et al. 2004). 
 In contrast to many solid tumours that exhibit a relation between the level of 
tumour vascularisation and prognosis, such as in breast cancer (Choi et al. 2005), 
lung cancer (Singhall et al. 2005) and prostatic carcinoma (Quinn et al. 2005), in 
melanoma the issue is more complicated and the prognostic importance of the degree 
of tumour vascularisation has remained controversial. Tumour vascularisation has not 
yet been evaluated in large matched cohorts of patients with melanoma. 
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2.5. Tenascin-C
In our study, the majority of the tumours expressed Tn-C, only two out of 98 being com-
pletely negative for Tn-C. A quantative difference in the expression of Tn-C has previ-
ously been reported in benign, dysplastic and malignant tumours. All benign nevi have 
shown moderate expression of Tn-C at the dermoepidermal junction, but at a markedly 
lower level than in malignant tumours (Tuominen and Kallioinen 1994). Tn-C is not spe-
cifi c to cancer but its upregulation is associated with processes such as organogenesis, 
wound healing and invasive growth.
 Our study was the fi rst, to our knowledge, to correlate the immunohistochemical 
fi ndings of Tn-C in melanomas with the prognosis for patients. Increased expression 
of Tn-C in the stroma of invasive regions or in the cytoplasm of malignant cells cor-
related with a poorer clinical course of the disease as compared with those lacking 
Tn-C expression, signifi cantly so in disease-free survival. In overall survival, the 
difference was not marked. This fi nding suggests that the appearance of Tn-C in 
the invasive regions is a sign of an active tumour with the capacity to grow inva-
sively and to metastasise. We did not study the expression of Tn-C with in situ hy-
bridisation and therefore the origin of Tn-C could be in extracellular matrix and/or 
melanoma cells. Evidence exists, however, that in regions of tumour invasion Tn-C 
is produced by cancer cells (Yoshida et al. 1997). The role of intracytoplasmic Tn-C 
in melanoma cells, aside from invasive regions, requires further investigation. There 
is no evidence that intracytoplasmic or extracellular matrix Tn-C is any different in 
structure or function. In this study we did not examine the different isoforms of Tn-C. 
Intracytoplasmic immunoreactivity may be a sign of signifi cant synthesis of Tn-C in 
these cells. 
 Clinical studies on the relevance of the level of Tn-C expression in malignant tu-
mours and its relation to patient survival have shown inconsistent results. Tn-C most 
likely has different roles in different tissues. Further, its function may differ, depend-
ing on whether it is located in invasion regions or inside the tumour. Moreover, dif-
ferent isoforms may have different functions (Chiquet-Ehrismann and Chiquet 2003). 
 Clearly, Tn-C cannot be a discriminate of malignancy; rather its expression might 
be regarded as a sign of the invasive character of the tumour. Future studies will 
show whether expression of Tn-C could be used as a prognostic marker and a tool in 
clinical treatment decisions for primary melanoma and whether it could be used as a 
target for immunotherapy. As Tn-C has also been detected in the sera of patients with 
advanced melanoma (Herlyn et al. 1991), it has potential as a serum marker for the 
progression of melanoma. 
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2.6. Ezrin 
Most of the primary melanomas (76/95) expressed ezrin in our study. Increased ezrin 
expression was associated with increased tumour thickness and Ki-67. Patients with high 
ezrin expression in primary melanomas showed a trend towards poorer disease-free sur-
vival than did those with low ezrin expression in tumours. However, in this rather small 
patient population the difference was not statistically signifi cant. For melanoma-specifi c 
overall survival there were no differences between tumours with or without ezrin immu-
noreactivity. Expression of ezrin was noted in all the metastatic samples of 12 patients, 
and the intensity in metastatic tumours was higher (n = 6) than in their primary counter-
parts or remained unchanged (n = 6). This interesting preliminary fi nding will have to be 
evaluated with a bigger patient population. 
 Although we detected no signifi cant association between ezrin expression and 
the prognosis of primary melanoma, there was evidence that ezrin expression is as-
sociated with tumour growth. This might be due to the involvement of ezrin in many 
intra- and intercellular processes that may directly contribute to the growth potential 
of the tumour. Another alternative is that ezrin is a marker of a melanoma cell that 
is responding to growth factors, adhesion molecules and other signalling pathways 
dependent on ezrin (Hunter 2004). 
 Activated ezrin possesses a central link at the cell membrane and cytoskeleton 
interface. It conducts signals between metastasis-associated cell-surface molecules 
and signal transduction components. Signals from the cell surface are passed through 
the Rho signal pathway or through the antiapoptotic molecule Akt, or MAPK (Hunter 
2004), which are important for successful metastasis (Khanna et al. 2004). Ezrin 
associates with the extracellular matrix mediated by integrins and takes part in the 
cell-cell interaction mediated by E-cadherin, both essential areas for a malignant cell 
in the invasive and metastatic processes (Hunter 2004). In melanoma, MAPK acti-
vation plays a key role in radial growth phase melanoma and at later stages (Cohen 
et al. 2002). The Ras-Raf-MAPK pathway is activated in the majority of melanomas 
because of a mutation in the BRAF gene (Collisson et al. 2003). In an experimental 
study on mice with metastasised melanoma, an inhibitor of MAPK phosphorylation 
was introduced, resulting in rapid regression of pulmonary metastases and inhibition 
of the formation of new ones (Collisson et al. 2003). Similarly, a previous report 
showed that inhibition of MAPK signalling in melanoma cells induced apoptosis, 
suggesting a direct role for MAPK in signalling malignant transformation of melano-
cytes and in survival (Koo et al. 2002). Enhanced ezrin expression in melanoma cells 
may therefore contribute to increased MAPK levels and thus infl uence tumour cell 
proliferation and metastasis.
 More clinical investigations on larger patient populations are awaited to enable 
us to further evaluate the role of ezrin in melanoma development and to determine its 
prognostic and possible therapeutic role in primary melanoma.
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2.7. Methodological aspects 
Compared with cell lines, immunohistochemistry can not directly answer to what are the 
background molecular mechanisms in the malignant progression of cutaneous melanoma 
and how the prognostic variables exert their infl uence on this disease (Newton Bishop 
1997). However, immunohistochemistry is generally rather specifi c and sensitive method 
and is routinely performed by many pathology laboratories. It is also important to test 
whether the theories on the molecular mechanisms in vitro apply in clinical materials, 
because the expression patterns and biological properties of cell lines may change during 
culture (Newton Bishop 1997, Bodey 2002). The weakness of immunohistochemistry 
is the poor standardisation. One major cause of variation in the reproducibility of im-
munohistochemical staining is induced by different tissue fi xation and processing. False 
interpretations may also be caused by tumour heterogeneity as the analysed specimen 
may not be representative (Bodey 2002). Studies differ in the manner in which the 
same antigen is quantifi ed. For instance, tumour vascularity can be quantifi ed by the 
number of vessels or by the maximum diameter of vessels per unit area of the tumour 
or by the percentage vessel area of the tumour area examined (Srivastava et al. 1988). 
Accordingly, Bcl-2 expression can be quantifi ed by intensity or the percentage of area 
expression or by multiplying these to obtain staining scores (Kallio et al. 2004). All 
of these different parameters affect the diversity of the immunohistochemical staining 
results and make comparison diffi cult. 
3. Future prospects
Evaluation of the stage and prognosis of melanoma can be expected to become more pre-
cise with the application of new technologies such as gene profi ling (DNA micro array) 
and reverse transcription polymerase chain reaction (RT-PCR) procedures. Imaging of 
patients with position emission tomography (PET) has turned out to be useful in de-
tecting occult micrometastatic disease and will achieve greater importance if effective 
treatment modalities are found. Ideally, both known and future tumour-related prognos-
tic markers would select the high-risk patients who would receive more intensive fol-
low-up and be the focus of adjuvant therapies. The majority, the low risk patients, would 
need less frequent or shorter follow-ups, thus reducing treatment costs. Moreover, these 
patients would be given a presumably favourable prognosis, which would contribute to 
their quality of life. Some of the known or future tumour-related prognostic factors may 
provide a basis for tailored melanoma therapy. Some tumour markers may also serve as 
predictive factors in assessing treatment response and in surveillance. 
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In our study on primary melanoma we reached the following conclusions:
1. In a Finnish population of 298 primary melanoma patients diagnosed during 
1988–1991 the melanoma-specifi c 5- and 10-year survival rates were 85.7% and 
82.1%, respectively; 91% of the melanomas were staged as local at the time of 
diagnosis. The most important prognostic factors were tumour thickness, level 
of tumour invasion, stage of tumour and tumour ulceration. Ulceration was an 
unfavourable prognostic marker. Younger patients had better survival outcomes 
than did older ones. Tumour location on the trunk was an adverse prognostic 
factor. In this series, surgical margins seemed to have no effect on survival. 
2. High expression of p53 was associated with poor disease-free survival. Increased 
expression of Bcl-2 was associated with other adverse prognostic markers (tumour 
ulceration, male gender and old age of the patient). In intermediate-thickness 
melanomas, an increased level of Blc-2 showed a trend towards poor survival. 
Expression of Ki-67 was not a prognostic marker for primary melanoma.
3. High vascularisation of primary melanomas was associated with a better prognosis 
but is not an independent prognostic indicator. 
4. In primary melanomas, absence of Tn-C in the stroma of invasion fronts and 
within tumour cells seemed to be related to more benign disease behaviour with 
a lower risk of developing metastases. 
5. Expression of ezrin in primary melanomas correlated with tumour proliferation 
(Ki-67), thickness and level of invasion, suggesting an association between ezrin 
expression and tumour progression. In survival analysis, expression of ezrin did 
not reach prognostic signifi cance. 
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